Detection and Mechanistic Comparison of Two Anti-Trypanosomal Diamidines in a Rat Renal Model by Goldsmith, Rachel B.
Detection and Mechanistic Comparison of Two Anti-
Trypanosomal Diamidines in a Rat Renal Model 
Rachel Beaulieu Goldsmith 
A dissertation submitted to the faculty of the University of North Carolina at Chapel 
Hill in partial fulfillment of the requirements for the degree of Doctorate in Philosophy 
in the Department of Pathology and Laboratory Medicine. 
Chapel Hill 
2011 
 
Approved by:  
Richard R. Tidwell 
James Edwin Hall 
John Charles Jennette 
David S. Miller 
Mary F. Paine 
Howard M. Reisner 
ii 
Abstract 
Rachel Beaulieu Goldsmith: Detection and Mechanistic Comparison of Two Anti-
Trypanosomal Diamidines in a Rat Renal Model 
(Under the direction of Richard R. Tidwell) 
 
There is an urgent need for new treatments for human African 
trypanosomiasis (HAT), a neglected parasitic disease indigenous to sub-Saharan 
Africa.  HAT progresses in two stages; the second stage is fatal without treatment.  
Current treatments for both stages are toxic or difficult to administer.  Pafuramidine 
was in phase III clinical trials for first stage HAT.  In an expanded phase I trial, 7% of 
patients experienced severe delayed nephrotoxicity resulting in the termination of 
the clinical development of pafuramidine.  Furamidine, the active diamidine 
metabolite of pafuramidine, was detected in rat kidney eight days after 
administration of pafuramidine, indicating it was likely the nephrotoxic agent.   
A second generation diamidine, CPD-0801, was shown to be highly active in 
first stage HAT mouse and primate models.  In addition, it is the only compound that 
is curative in both second stage HAT mouse and primate models.  While the in vivo 
results for CPD-0801 are exciting, it has the drawback of being structurally related to 
furamidine.  For this molecule to proceed to clinical trial, it must be demonstrated 
that CPD-0801 is less likely to induce nephrotoxicity than pafuramidine.   
The current study determined that rat kidney exposure to CPD-0801 was 14 
times less than furamidine.  This discovery was a positive indication that CPD-0801 
iii 
may have less potential for the delayed nephrotoxic effect.  In an effort to explain 
this promising finding, a series of studies were designed and executed.     
Based on imaging and transport studies, CPD-0801 and furamidine can enter 
tubule cells independent of organic cation transporters 1/2, and exit possibly through 
multidrug and toxin extruder.  Additionally, due to intracellular binding, five times 
more CPD-0801 was freely available for transport.  While the transport data may 
explain the cell specificity of diamidines, binding may explain differences in 
accumulation and excretion.  Future studies should be aimed at defining and 
measuring the intracellular binding of this molecule. 
Based on this work, CPD-0801 has improved accumulation, binding and 
excretion characteristics as compared to furamidine in rat kidney.  These data may 
indicate that CPD-0801 is less likely to be nephrotoxic than furamidine.  Therefore, 
development of CPD-0801 for second stage HAT should continue.   
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Chapter 1:  
Introduction 
 
A safe, effective treatment for both first and second stage human African 
trypanosomiasis (HAT) is in development by the Consortium for Parasitic Drug 
Development (CPDD).  The diamidine compound, CPD-0801 (2,5-Bis[5-amidino-
2-pyridyl]furan), is highly efficacious in rodent (Wenzler et al., 2009) and simian 
(Thuita 2010, unpublished work) disease models of second stage 
trypanosomiasis.  However, it is closely related structurally to furamidine, the 
active form of pafuramidine, which was found to be active against first stage HAT 
in phase II and III clinical trials.  Development of pafuramidine was halted when 
the treatment demonstrated nephrotoxicity in an expanded phase I clinical trial.  
To move CPD-0801 into clinical trials, it must be demonstrated that it is unlikely 
to have nephrotoxic side-effects.   
The purpose of this work is to evaluate the possible nephrotoxicity of a 
new potential HAT treatment.  The new treatment, CPD-0801, will be compared 
to the previously unsuccessful compound, pafuramidine, in a rat renal model.  
Any differences observed between the two compounds will be thoroughly 
investigated with specific attention to how those differences may affect potential 
nephrotoxicity.  Before endeavoring to introduce a new treatment for HAT, it is 
necessary to first understand the nature of HAT and the current treatments.   
2 
Human African Trypanosomiasis 
Human African trypanosomiasis (HAT) is a neglected parasitic disease 
indigenous to sub-Saharan Africa (Figure 1).  In 2006, estimates suggested that 
between 50,000 and 70,000 people were infected with HAT (WHO, 2006), with 
up to 60 million at risk for the disease (Regional Committee for Africa, 2005).  It 
was reported in 2009 that, new cases of HAT decreased below 10,000 for the 
first time in 50 years (Simarro et al., 2010; Simarro et al., 2011).  Although the 
incidence of HAT may be lower than that of other tropical diseases, it remains 
one of the most neglected diseases in Africa according to the World Health 
Organization (WHO) (Regional Committee for Africa, 2009b).  Additionally, HAT 
leads the infectious disease world when accounting for disability adjusted life 
years (DALYs), estimated at 2.05 million years lost in 1999 (WHO, 2000) and 
1.54 million years lost in 2002 (Regional Committee for Africa, 2009a).  These 
years of productivity are lost because of the long length of illness, which usually 
includes hospitalization.  The lifelong impact of HAT, even after a patient is 
cured, includes developmental delays in children, which hinder a child‟s ability to 
contribute effectively to society as an adult (Regional Committee for Africa, 2005; 
Fevre et al., 2008).  Because HAT has the highest disease incidence in the 15-45 
year old age range, the time and productivity lost due to HAT infection represents 
a major economic concern (Regional Committee for Africa, 2005).   
The impact and danger of HAT can be underestimated due to the cyclical 
nature of epidemics.  Since the disease was recognized, there have been three 
known epidemics: early 1900s, 1920s and 1970 to 2008 (Regional Committee for 
Africa, 2005).  The fluctuations in disease incidence are partially due to blatant 
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Figure 1 Annual number of human African trypanosomiasis cases 
reported to the WHO from 2000 to 2007.  Red line roughly 
demarcates T. b. gambiense from T. b. rhodesiense.   
Adapted from 
http://www.who.int/trypanosomiasis_african/disease/en/index.html  
 
4 
neglect of HAT control during times of low incidence, which allows the disease to 
flourish until it reaches a level at which it cannot be ignored.  This neglect is not 
surprising, as HAT is primarily found in Sudan, Angola and the Democratic 
Republic of Congo (Figure 1) (WHO, 2006), where political instability and war 
result in lapses in HAT control programs (Berrang-Ford et al., 2010).  Vector 
control is one of the most effective methods of HAT control due to the highly 
specific habitat of the tsetse fly.  These practices include sequential aerosol 
spraying technique, ground spraying, insecticide-treated targets or insecticide-
treated animals (live baits), the use of traps, and the sterile insect technique 
(WHO expert committee, 1998).  Unfortunately, the destabilization of 
governments in the region renders these programs difficult for external 
organizations (such as the WHO) to enact and a low priority for internal 
organizations (Berrang-Ford et al., 2010).  Any relaxation in control efforts could 
result in another HAT epidemic.  Effective long-term control or elimination of HAT 
is only possible through the development of safe, highly efficacious drugs that 
are easy to administer in this area of limited healthcare resources (Simarro et al., 
2011).   
HAT is caused by infection with a single celled parasite, Trypanosoma 
brucei gambiense or T. b. rhodesiense (Welburn et al., 2001).  The parasite is 
transmitted via the tsetse fly, whose specific habitat accounts for the geographic 
restriction of the disease (Glover, 1967).  Upon infection, the parasite circulates 
in the blood and lymph of the host; this is called the hemolymphatic or first stage 
of disease.  Symptoms of the first stage of HAT can be flu-like and include 
5 
headache, fever and inflammation at the site of the bite (Chappuis et al., 2005; 
Kennedy, 2006).  Unfortunately, these symptoms are often not severe enough for 
the host to seek medical attention.  During the first stage of disease, the parasite 
evades the immune system by constantly altering the variant surface 
glycoprotein (VSG), which coats the surface of the trypanosome (Pays, 2006).  
Most of the parasites will be recognized and destroyed by the host‟s immune 
system, so an alternative low-frequency VSG becomes the dominant variant and 
parasitemia rises.  This cycle will repeat, creating waves of increasing and 
decreasing parasitemia throughout the hemolymphatic stage of disease.  The 
ability of the parasite to avoid the host immune system by altering VSG also 
renders vaccine development difficult (Magez et al., 2010).  Additionally, it seems 
that trypanosomes may be capable of actively destroying the B-cell memory 
compartment as demonstrated by abolishment of the pertussis vaccination 
response (human DTPa vaccine against diphtheria, tetanus and B. pertussis) 
upon subsequent T. brucei infection in mice (Radwanska et al., 2008).  This 
further complicates HAT vaccine development making drug development a 
superior choice for HAT control.   
The first stage of HAT can last from a few months to 10 years.  The 
duration is dependent on the strain.  Rhodesiense (also known as acute HAT) 
progresses much more rapidly than gambiense (also known as chronic HAT) 
(Barrett et al., 2007).  If untreated, the trypanosomes will cross the blood brain 
barrier and multiply in the extracellular fluid of the central nervous system (CNS).  
This is known as the CNS or second stage of disease.  The many neurological 
6 
symptoms that may occur during second stage HAT are likely due to 
perturbations in pro- and anti-inflammatory responses of the host immune system 
(Kennedy, 2006).  CNS stage HAT is typified by the most prominent symptom, 
daytime somnolence and nighttime insomnia, giving it the colloquial name 
„sleeping sickness‟ (Chappuis et al., 2005; Kennedy, 2006; WHO, 2006).  The 
precise duration of morbidity during second stage disease is unknown.  Due to 
the difficulty in staging the disease, there are few studies available.  Without 
treatment, second stage HAT leads inevitably to coma and death.   
Current Treatments for HAT 
HAT is considered a neglected or orphan disease, largely due to the lack 
of interest in pursuing new treatments.  Most of the current treatments for HAT 
were developed over 50 years ago, including suramin and pentamidine for first 
stage, and melarsoprol and eflornithine for second stage (Figure 2) (Barrett et 
al., 2007).  The most recently developed HAT treatment, nifurtimox, in 
combination with eflornithine, for second stage, originated as a therapeutic for 
other parasitic diseases (Barrett et al., 2007; Yun et al., 2010).  All treatments 
approved for HAT by the WHO must be delivered parenterally and are toxic, 
making them non-ideal for treatment in sub-Saharan Africa, where patients may 
have limited hospital access.  The lack of safe, curative and affordable 
medications for HAT contributes to the lack of control of this disease (Regional 
Committee for Africa, 2009a).   
For more than 60 years, the predominant treatment for first stage HAT has 
been pentamidine (Lutje et al., 2010).  While pentamidine continues to effectively  
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Figure 2 Compounds currently approved for HAT treatment by the WHO.  
Pentamidine and suramin are used for first stage.  Melarsoprol, eflornithine and 
eflornathine in combination with nirfurtimox are used for second stage treatment.  
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treat first stage HAT, it must be given by intravenous or intramuscular injection, 
and it is hepatotoxic, nephrotoxic (not dose limiting) and induces severe 
dysglycemia (Assan et al., 1995).  Additional treatments for the hemolymphatic 
stage include suramin, which can only treat T. b. rhodesiense and is therefore of 
limited utility, as T.b. gambiense HAT comprises 90% of HAT cases (WHO, 
2006; Barrett et al., 2007).   
Melarsoprol, an arcenical, is the most widely used compound for treating 
second stage HAT, and it is the only compound currently capable of treating CNS 
stage T. b. rhodesiense (Kennedy, 2006; Barrett et al., 2007).  Introduced in 
1949, melarsoprol has been given in a variety of treatment regimens.  Traditional 
regimens require hospitalization for 25 to 36 days and thus place an undue 
economic strain on hospitals and families (Moore, 2005).  More recently a 10 day 
dosing regimen has been shown to be as effective as the 25 day regimen.  
However, the shorter regimen has the same severe toxicities (Pepin and Mpia, 
2006).  Melarsoprol continues to be the dominant CNS stage HAT treatment 
despite its numerous and potentially fatal adverse events.  These events include 
cardiac and neurological toxicities, most notably the associated post-treatment 
reactive encephalopathy (PTRE) that occurs in 10% of patients, half of whom die 
(Kennedy, 2006; Pepin and Mpia, 2006; Barrett et al., 2007).  The toxicity of 
melarsoprol has been tolerated for the last six decades because it is highly 
effective and there have been no economically feasible alternatives.  However, 
resistance may have developed over that time, as the number of treatment 
failures with melarsoprol was found to be 19.5% from 2001 through 2003 
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(Robays et al., 2008) compared to only 5-8% as previously reported (Pepin et al., 
1994; Schmid et al., 2005), although no melarsoprol-resistant trypanosomes 
have been found.  The increase in treatment failures and the extremely toxic 
nature of melarsoprol makes its replacement a priority.    
Eflornithine has been used to treat second stage HAT in T. b. gambiense 
patients since 1981 and was FDA-approved in 1990 (Lutje et al., 2010).  It has 
many adverse side effects, similar to those of cytotoxic chemotherapy, which are 
usually reversible after treatment, unlike melarsoprol-associated toxicities (Burri 
and Brun, 2003).  The four daily infusions for 14 days required for treatment with 
eflornithine makes it impractical for point-of-care use in the rural areas where 
HAT is largely found.  Its high cost of treatment ($350 per patient in 2003) makes 
widespread use unrealistic, leaving melarsoprol the dominant treatment (Burri 
and Brun, 2003).  To overcome these major difficulties in delivery and cost, a 
combination treatment of eflornithine and nifurtimox has been developed to limit 
the amount of eflornithine required (Yun et al., 2010).   
Nifurtimox was originally developed as an oral treatment for American 
trypanosomiasis, Chagas‟ disease, but when used in combination with 
eflornithine, it is effective against second stage HAT and has a more desirable 
treatment regimen than eflornithine alone (14 eflornithine injections over 7 days 
with oral nifurtimox 1/day for 10 days, instead of 56 injections over 14 days) (Yun 
et al., 2010).  Nifurtimox/eflornithine combination therapy (NECT) requires 
complex transport services, as well as extensive training of medical personnel to 
administer the medication (Yun et al., 2010).  Despite the improvement in the 
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treatment regimen using NECT, the challenges in administering this therapy in 
rural sub-Saharan Africa make it a far from optimal solution for second stage 
HAT.  A point-of-care treatment that can be used in rural clinics is still not a 
reality for this deadly disease.   
Simultaneous treatment of both stages of HAT is ideal due to the difficulty 
in distinguishing first and second stage.  Staging of HAT is essential because the 
treatments for CNS stage HAT are so toxic that they cannot be administered 
without diagnostic confirmation.  Diagnosis cannot be made by symptoms alone 
and requires a lumbar puncture to count the number of parasites or white blood 
cells in the cerebrospinal fluid (Chappuis et al., 2005; Lutje et al., 2010).  Lumbar 
puncture is particularly difficult in rural regions where this disease occurs due to 
the lack of medical facilities.  Of the treatments currently approved for HAT or in 
clinical trials (NECT), none of them can be used to treat both first and second 
stage HAT due to lack of efficacy against second stage HAT, an unacceptably 
high risk of adverse events, or insufficient access due to cost and impractical 
dosage regimes.  A low-toxicity drug that could be given to both first and second 
stage patients, without the need for a lumbar puncture, could greatly improve 
patient compliance and the breadth of locations that could be reached for 
treatment, since specialized health professionals may no longer be needed for 
staging purposes.   
Both first and second stage HAT demand new treatments.  An orally 
bioavailable compound with low toxicity (preferably low enough to use as a 
prophylactic) would be ideal for first stage treatment.  CNS stage HAT patients 
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are in desperate need of safe, easily administered compounds that are effective 
against both stages of disease.   
HAT Treatments Developed by the Consortium for Parasitic Drug 
Development (CPDD) 
Furamidine was in development for first stage HAT, and the structurally 
similar compound, CPD-0801, is currently in development for second stage HAT 
by the CPDD.  Both compounds are pentamidine analogs, which are members of 
the class of compounds termed diamidines (Figure 3).  They were selected for 
development due to their efficacy in vitro and in vivo (Table 1) (Wenzler et al., 
2009).  Based on their properties, namely logD (a measure of pH-dependent 
lipophilicity) (Table 3), and in vivo data, it has been shown that both furamidine 
and CPD-0801 are not sufficiently active orally.  Therefore, a prodrug approach 
was used.  Pafuramidine and CPD-0868 are bis-O-methylamidoxime prodrugs of 
furamidine and CPD-0801, respectively.  These prodrugs are orally bioavailable 
and, after absorption, are converted to the active molecules (Figure 4).   
Pafuramidine, the orally bioavailable prodrug of furamidine, showed 
efficacy in the first stage of disease in human clinical trials.  Unfortunately, phase 
III clinical trials of pafuramidine were terminated due to results from an expanded 
phase I study, which revealed unexpected delayed nephrotoxicity (see Table 2 
for clinical trial details) (Pholig et al., 2008; Mdachi et al., 2009).  Of the 80 
healthy men and women in the extended phase I safety study, six experienced 
nephrotoxicity 42 to 60 days after the last dose (100 mg/kg BID for 14 days).  Of 
those six, five were classified as having acute renal failure, all of whom 
recovered with treatment.  Pathology indicated tubulointerstitial nephritis (TIN) 
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Figure 3 Compounds efficacious against HAT in rodents, monkeys or 
humans.  Furamidine and its prodrug, pafuramidine, were in development 
for first stage HAT.  CPD-0801 and its prodrug, CPD-0868, are in 
development for second stage HAT.  
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Furamidine CPD-0801 
In vitro IC50 (ng/mL) 1.0 6.5 
1st stage in vivo 
STIB900 mouse model 
4 d x 10 mg/kg: 4/4a 
4 d x 5 mg/kg: 4/4a 
1 d x 10 mg/kg: 4/4a,b 
2nd stage in vivo 
GVR35 mouse model 
10 d x 12.5 mg/kg: 1/4a 10 d x 20 mg/kg: 4/4a 
Toxicity observed 10 d x 25 mg/kg: fatala,c none 
Table 1 In vitro and in vivo efficacy data for furamidine and CPD-0801.   
Data from Wetzler, et al., 2009.  In vitro IC50 was done in the STIB900 strain of T. 
b. rhodesiense.  X/4 represents the number of cured animals (as defined by the 
study) out of four.   
a intraperitoneal administration 
b intravenous administration 
c acute fatal toxicity  
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Figure 4 General metabolism of bis-O-methylamidoxime prodrug to active diamidine.  Both 
pafuramidine (X=C) and CPD-0868 (X=N) are thought to be metabolized in a similar manner.  
Pafuramidine metabolic scheme is based on previous studies (Saulter et al. 2005; Wang et 
al. 2006; Generaux, 2010).  Recent work by C. Generaux (Generaux, 2010) indicates an 
alternate metabolic pathway from prodrug directly to M3.  
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Clinical Trial Subjects Dose Safety 
Phase I 
66 Healthy  Men 
(Germany) 
1 x 25-600 mg 
No safety 
concerns 
Phase I 
36 Healthy Men 
(Germany) 
20, 50, or 100 mg 
BID x 5.5 d 
No safety 
concerns 
Phase II & III 
416 First Stage 
Patients 
(Africa) 
100 mg/kg BID x 5 d 
or BID x 10 d 
Minimal toxicity, 
less than 
pentamidine 
Expanded 
Phase I 
80 Healthy Men 
and Women 
(South Africa) 
100 mg BID x 14 d 
Toxicity 
observed, liver 
and kidney 
Table 2 Summary of select pafuramidine HAT clinical trials 
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with tubular epithelial damage, which may be a component of TIN (Jennette, 
2008b; Jennette, 2010; Olson, 2010).  Minimal change disease was also thought 
to be present in one subject.  These findings indicate that pafuramidine-induced 
nephrotoxicity occurred in 7% of subjects, but the mechanism of the toxicity 
remains unknown.  However, the toxicity was noted only after the increase in 
dosage of pafuramidine, from a 10-day to 14-day regimen, suggesting that 
accumulation of compound in the kidney may be associated with toxicity due to 
increased tissue exposure.  Although pafuramidine was shown to be less toxic 
than pentamidine in phase II and III trials using the 10 day regimen, the program 
was terminated due to delayed nephrotoxicity.  To date, no orally active drugs 
are available for treatment of first stage HAT.   
CPD-0801, potentially less toxic then pafuramidine, is in development for 
second stage HAT, although it is efficacious in both first and second stage 
murine models (Wenzler et al., 2009).  CPD-0801 was selected for its in vitro 
efficacy and lower DNA binding (Table 3).  The decreased binding of CPD-0801 
to A-T rich DNA compared to furamidine was thought to be encouraging because 
DNA binding could have been related to toxicity, although data to support that 
contention is lacking (Table 3).  In vivo, CPD-0801 is curative in the standard 
STIB900 early stage mouse model at a single dose of 10 mg/kg IV or IP (Table 
1) (Tanja Wenzler, Reto Brun unpublished data).  This is a significant 
improvement over furamidine which cured only three out of four mice at a higher 
dose of 20 mg/kg IP for four consecutive days (Wenzler et al., 2009).  
Additionally, CPD-0801 is also curative in the GVR35 CNS stage mouse model  
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Furamidine CPD-0801 Pafuramidine CPD-0868 
pKa 10.4, 11.8 10.0, 10.4 2.5, 4.1 2.8, 2.2
a 
logD (pH 7.4) > -2.0 -3.3 3.5 2.6a 
ΔTm (A-T rich DNA) 26.2 16 -- -- 
ΔTm (oligomer) 8.9 8.4 -- -- 
Table 3 pKa, logD and DNA binding of anti-trypanosomal compounds.   
From Mathis et al., 2007, and S.K Jones (personal communication).   
a Calculated using ACDlabs version 11.0 
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at 20 mg/kg IP for 10 days, a dose at which furamidine is ineffective and acutely 
toxic (Wenzler et al., 2009).  Since CPD-0801 is efficacious in both first and 
second stage disease and seems to have acceptable levels of toxicity, it appears 
to be a promising candidate for further drug development, as it meets many of 
the target product profile.  If CPD-0801 were to be approved for human use, 
patients may not need to be staged prior to treatment.   
Although CPD-0801 can be given IM like pentamidine, an oral drug would 
be ideal.  CPD-0868 is the orally bioavailable bis-O-methylamidoxime prodrug of 
CPD-0801 (Figure 3) and is also efficacious in both the hemolymphatic and CNS 
stage mouse models of HAT (Wenzler et al., 2009).  It is thought that CPD-0868 
is metabolized to CPD-0801 in a similar manner to the metabolism of 
pafuramidine to furamidine (Figure 4) (Saulter et al., 2005; Wang et al., 2006; 
Generaux, 2010).  If CPD-0868, or any other bis-O-methylamidoxime prodrug, is 
ever to be developed, it must be demonstrated that the prodrug pafuramidine and 
its associated intermediate metabolites did not cause the delayed nephrotoxicity.  
Confirming that the prodrug and associated metabolites were not the nephrotoxic 
agents would allow active diamidines to be compared directly.  Active diamidine 
can be administered and measured directly, with minimal metabolism, making it 
easier to modulate plasma and tissue exposure.  Although CPD-0868 is 
efficacious and orally bioavailable, it is simpler to ensure that CPD-0801 is less 
likely to be nephrotoxic than pafuramidine because it lacks metabolites.  
Therefore, CPD-0801 is the primary compound in development for HAT 
treatment.   
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Development of CPD-0801 potentially meets the urgent need for a highly 
effective, minimally toxic alternative to melarsoprol.  However, given the 
nephrotoxic side-effects of pafuramidine, the potential toxicity of CPD-0801 is a 
major concern.  The low incidence (7%) and limited understanding of 
pafuramidine-induced delayed nephrotoxicity in humans makes replicating this 
toxicity in an animal model extremely difficult, although the attempt is ongoing 
(DeSmet, 2010).  Because a rodent model that replicates pafuramidine-induced 
delayed nephrotoxicity is lacking, accumulation and distribution of CPD-0801 in 
rat kidney will be compared to pafuramidine.  Assessing the potential kidney 
toxicity of CPD-0801 in pre-clinical studies is essential for the continuation of 
CPD-0801.  For this reason, understanding the mechanism of toxicity of the now 
abandoned compound, pafuramidine, continues to be of importance.   
Toxicity and Accumulation 
Drug-associated nephrotoxicity is damage to the kidney caused by an 
exogenous compound given to the patient and is distinct from that related to the 
etiology or pathogenesis of the disease.  Clinically, drug-associated kidney 
toxicity manifests most often as acute renal failure (ARF), chronic kidney disease 
and/or nephritic syndrome (Greenberg, 2009).  In the expanded phase I safety 
study, five subjects were described as having ARF based on blood urea nitrogen 
(BUN) and creatinine levels.  Of the five patients, only two had kidney biopsies 
taken.  The biopsies indicated both TIN and some acute tubular necrosis (ATN), 
known components of ARF.  Based on the pathology, pafuramidine-induced 
delayed nephrotoxicity may be similar to that produced by other drugs known to 
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cause ARF.  The clinical presentation and pathology of pafuramidine-induced 
delayed nephrotoxicity was compared to a variety of known nephrotoxic 
compounds (Table 4).  Understanding the similarities and differences in kidney 
toxicity of other drugs may aid in the understanding of pafuramidine-induced 
delayed nephrotoxicity.   
The most unusual aspect of pafuramidine-induced delayed nephrotoxicity 
was its occurrence 42-60 days post administration.  Most nephrotoxicities are 
acute and generally occur while the patient is still being dosed.  There are 
compounds that cause toxicity several days or months after the first dose 
(including non-steroidal anti-inflammatory drugs, NSAIDs, and proton pump 
inhibitors), although dosing is usually still ongoing when symptoms first present 
clinically (Greenberg, 2009).  Secession of NSAID dosing usually leads to 
spontaneous remission of the nephrotoxicity (Greenberg, 2009).  Allergic 
interstitial nephritis, drug-associated nephrotoxicity due to an immune response 
after repeat exposure, generally presents less than one month after exposure 
(Greenberg, 2009).  There are no common examples of drug-associated 
nephrotoxicity weeks or months after the last dose (Schrier, 2007; Greenberg, 
2009) as observed with pafuramidine.   
NSAIDs and several antibiotics have been associated with TIN (Eknoyan 
and Khosla, 2007; Jennette, 2008a).  TIN is an inflammatory condition of the 
interstitial tissue between the tubules that often occurs in patients with ARF 
(Schrier, 2007; Greenberg, 2009).  The inflammatory lesions present in TIN are 
comprised of moderate edema and leukocytes, mostly activated T lymphocytes,  
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Compound 
Delayed 
clinical 
presentation 
TIN 
observed 
ATN 
observed 
Associated 
with 
accumulation 
pafuramidine     
NSAIDs 
 
 
  
aminoglycosides 
  
  
cephalosporins 
 
   
acyclovir 
   
 
cisplatin 
  
*  
Table 4 Characteristics of drug-associated nephrotoxicities.   
NSAIDS include fenoprofen, ibuprofen, naproxen, rofecoxib and celecoxib 
(Greenberg, 2009).   
TIN: tubulointerstitial nephritis 
ATN: acute tubular necrosis 
*associated with progression to chronic tubulointerstitial disease (Dentino et al., 
1978)  
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mononuclear cells, and less than 10% eosinophils (Schrier, 2007; John and 
Herzenberg, 2009).  TIN is typified by tubular inflammation, mostly in the cortex 
and corticomedullary junction, with very little glomerular or vesicular involvement 
(Schrier, 2007; John and Herzenberg, 2009).  TIN may not be dose-dependent 
because it is initiated upon antigen presentation by either interstitial or tubular 
epithelial cells, potentially subsequent to tubular damage (Eknoyan and Khosla, 
2007).  For example, TIN is part of the nephrotoxicity associated with many 
compounds, including pafuramidine.   
Aminoglycosides, another class of drugs known for their associated 
nephrotoxicity, may share some commonalities to pafuramidine-induced delayed 
nephrotoxicity.  Aminoglycosides are known for causing acute tubular necrosis 
(ATN) as opposed to TIN.  However, some minor ATN was seen in biopsies from 
subjects given pafuramidine (Olson, 2010).  Similar to furamidine, 
aminoglycosides are cationic and cannot freely cross membranes.  However, 
unlike pafuramidine, aminoglycosides are almost exclusively eliminated through 
the urine (MacDonald et al., 1983; Greenberg, 2009), helping to explain their 
nephrotoxicity.  Accumulation of aminoglycosides in the renal cortex is 
hypothesized to be the cause of the nephrotoxicity.  While the specific cellular 
mechanism is still unknown, it is thought to be related to phospholipid catabolism 
(Mingeot-Leclercq et al., 1995; Sundin et al., 2001).  The toxicity is reversible, 
although with a lag time believed to be related to the kinetics of aminoglycoside 
accumulation and excretion (Schmitz et al., 2002; Nagai and Takano, 2004).  
Urinary excretion of aminoglycosides has been detected for days after the last 
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dose (Kaloyanides, 1984; Schrier, 2007; Greenberg, 2009).  As will subsequently 
be discussed in this work, aminoglycoside accumulation and subsequent 
nephrotoxicity may be similar to pafuramidine-induced delayed nephrotoxicity.  A 
connection between accumulation and nephrotoxicity may be indicated by the 
distinctive pattern of localization detected in the kidney of rats treated with 
radiolabeled pafuramidine (Figure 5).   
Nephrotoxicity associated with other compounds may have aspects similar 
to pafuramidine-induced delayed nephrotoxicity.  Cephalosporins are antibiotics 
known to induce ARF, demonstrating both TIN and ATN (Barza, 1978; 
Greenberg, 2009; John and Herzenberg, 2009).  Cephalosporin nephrotoxicities 
increase at higher doses (Barza, 1978).   Because cephalosporins are excreted 
renally, the dose-dependent toxicity indicates a direct relationship between 
kidney exposure and toxicity.  Acyclovir is a herpes antiviral that undergoes 
tubular secretion in the kidney causing increased renal tissue levels throughout 
treatment (Brigden and Whiteman, 1983).  The increasing levels of acyclovir are 
associated with nephrotoxicity, but the mechanism is thought to be associated 
with drug precipitation in the tubule lumen, causing obstruction (Sawyer et al., 
1988).  In contrast, there was no clinical evidence to suggest that precipitation of 
the drug or metabolites was involved in pafuramidine-induced delayed 
nephrotoxicity.  No precipitate or crystals were noted in the urine or biopsies of 
pafuramidine-induced delayed nephrotoxicity patients as they are with acyclovir.  
Additionally, obstruction-based nephrotoxicities are generally observed during or 
immediately after treatment (Greenberg, 2009).   
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Figure 5 Pafuramidine accumulation in rat.  Distribution of radioactivity in 
a male albino rat 24 h after oral 14C-pafuramidine (10 mg/kg).  White arrow 
indicates liver.  Black arrow indicates kidney.  Courtesy of Dr. James L. 
Allen (Immtech International, Incorporated).   
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Cis-diamminedichloroplatinum II (cisplatin), a cationic small molecule, is a 
chemotherapeutic known for its accumulation in the kidney and associated 
potentially fatal nephrotoxicity.  Cisplatin nephrotoxicity is characterized by 
patchy areas of proximal tubule destruction (ATN), significant distal tubule and 
collecting duct damage, interstitial fibrosis and platinum buildup (Dentino et al., 
1978).  While the pathology of cisplatin-induced nephrotoxity may differ from 
pafuramidine-induced delayed nephrotoxicity, cisplatin is a prime example of the 
connection between accumulation and toxicity.  It has been demonstrated in vitro 
and in vivo that cisplatin is a substrate of organic cation transporter 2 (OCT2), an 
uptake transporter found in the basolateral membrane of renal proximal tubule 
cells (Yonezawa et al., 2006; Filipski et al., 2008; Filipski et al., 2009; Tanihara et 
al., 2009).  When using either OCT1/2 knockout mice or co-administration of the 
OCT2 inhibitor imatinib, cisplatin uptake into the kidney and its subsequent 
toxicity decreases (Filipski et al., 2009; Tanihara et al., 2009).  Additionally, in 
mice deficient of multidrug and toxin extruder (MATE1), an efflux transporter in 
the apical membrane of renal proximal tubule cells, cisplatin concentrations in the 
kidney and plasma were higher, and toxicities were exacerbated, compared to 
control (Nakamura et al., 2010).  The connection between uptake, efflux and 
nephrotoxicity in cisplatin treatment was demonstrated through the study of 
transporters.  Analogous to the work done with cisplatin, identifying kidney 
transporters for which pafuramidine and/or its metabolites are potential 
substrates may yield further mechanistic understanding pafuramidine-induced 
nephrotoxicity.   
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As with aminoglycosides, cephalosporins, acyclovir and cisplatin, tissue 
accumulation of pafuramidine and/or its metabolites may correlate with potential 
kidney toxicity.  The potential for the active diamidine metabolite, furamidine, to 
be the nephrotoxic moiety is concerning due to its structural similarity to CPD-
0801.  It is essential for the development of CPD-0801 to ensure that it is less 
likely to be nephrotoxic than pafuramidine.  However, currently understood 
mechanisms of drug-associated nephrotoxicity do not explain pafuramidine-
induced delayed nephrotoxicity.  Given the lack of a known mechanism of 
toxicity, accumulation and localization of CPD-0801 could be compared to 
pafuramidine, and its active diamidine furamidine, to assess potential 
nephrotoxicity.   
Localization in the Kidney 
Localizing CPD-0801 and furamidine in the kidney may provide 
information about the behavior of these compounds in the kidney because 
pafuramidine nephrotoxicity was observed in specific locations, TIN was found 
primarily in the proximal tubules, especially within the corticomedullary junction 
(Olson, 2010).  To utilize localization effectively, the overall organization of the 
kidney must be understood.   
The kidney is organized by function.  Each segment of the nephron, the 
functional unit of the kidney, is found in a specific area.  The outer edge, called 
the cortex, contains glomeruli, proximal and distal convoluted tubules and 
collecting ducts (Figure 6).  The medulla is divided into inner and outer portions.  
The innermost portion contains loops of Henle and collecting ducts, and the outer  
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Figure 6 Schematic of kidney structure.  The kidney has three distinct 
regions: cortex, outer medulla (outer stripe and inner stripe), and inner 
medulla.  Each region contains different portions of the nephron.  
Adapted from Netter (Netter, 1973).  
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portion contains the two stripes (inner and outer).  The inner and outer stripes 
differ in that only the outer stripe contains thick strait proximal tubules (the pars 
recta).  The tubular epithelial cells in the proximal tubules are the most likely cell 
type for accumulating and/or secreting furamidine and CPD-0801, as they 
contain a large number of organic cation transporters on both the basolateral 
(blood side) and apical (filtrate or urine side) surfaces (Figure 7).  If these 
transporters are involved, then diamidines should be localized to proximal tubule 
cells.   
Visualization of both CPD-0801 and furamidine can be done by 
fluorescence, with excitations of 356 nm and 359 nm respectively, and emissions 
of 433 nm and 458 nm (Mathis et al., 2007).  It was shown that binding to A-T 
rich DNA quenches fluorescence of CPD-0801 86% and furamidine 17% which 
may affect diamidine visibility in the nucleus and mitochondria (Mathis et al., 
2007).  Therefore, inherent fluorescence of CPD-0801 and furamidine is an 
unreliable method of visualization because it cannot be assured that all 
compound present is visualized.  The potential to observe false negatives as a 
result of DNA binding is a drawback that must be overcome to fully study CPD-
0801 localization in the kidney.  To circumvent these issues, this work pursues a 
monoclonal antibody approach based on previous work done with an anti-
pentamidine polyclonal antibody (Reisner et al., 2000).   
Transporters in Proximal Tubule Cells 
The proximal tubule epithelium is the primary site of regulation in the 
kidney of endogenous organic cations (e.g., choline, epinephrine, dopamine)  
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Figure 7 Common organic cation transporters found in renal proximal 
tubules.  Solid arrows represent previously demonstrated transporters of 
furamidine and CPD-0801; dashed arrows represent possible transporters 
for which diamidines may be substrates.  Transport proteins are as follows: 
OCT1/2: organic cation transporter 1/2; ENT1: equilibrative nucleoside 
transporter 1; MATE1: multidrug and toxin extruder 1; OCTN1/2: organic 
cation (carnitine) transporter-novel 1/2; MRP2/4: multidrug resistance 
protein 2/4; MDR1: multidrug resistance transporter 1; CNT1: concentrative 
nucleoside transporter 1.   
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(Besseghir et al., 1981; Wright and Dantzler, 2004) and elimination of exogenous 
organic cations, including many drugs and toxins (Lee and Kim, 2004; Moe et al., 
2008).  Soluble organic cations are removed from the blood into the filtrate by 
glomerular filtration or directly into the tubule cells.  Compounds are sorted and 
eliminated by the kidney according to size, charge and hydrophobicity.  Larger, 
more hydrophobic compounds often move directly from the plasma, through the 
basolateral membrane, into proximal tubule cells.  Smaller, charged molecules 
can be selectively taken into the cell by transport proteins from the filtrate (a 
process known as reabsorption) or from the plasma.  Since the filtration system 
in the kidney must deal with a variety of molecules, there are many different 
molecule-specific transporters involved.  This discussion will focus primarily on 
transport of small organic cations that may be involved in uptake and efflux of 
diamidines (Figure 7).   
Organic cations generally require a transporter to move from the plasma, 
across the basolateral membrane, and into proximal tubule cells.  The most 
common transporters in the kidney are organic cation transporters 1 and 2 
(OCT1 and OCT2), which are known to be expressed along the basolateral 
membrane of the proximal tubule (Karbach et al., 2000; Lee and Kim, 2004).  
OCT1 is found primarily in the earlier portions of the proximal tubule found in the 
cortex, whereas OCT2 dominates the later portion, including the pars recta found 
in the cortex and outer stripe (Karbach et al., 2000).  OCT1 and OCT2 are known 
for their broad substrate specificity (Ullrich et al., 1992).  Therefore, it is expected 
that CPD-0801 and furamidine could use OCT1 and/or OCT2 as the primary 
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entrance into the proximal tubule cells of the kidney from the plasma.  CPD-0801 
and furamidine are both substrates of OCT1 (Figure 8).  Furamidine is also a 
substrate of OCT2 (Ming et al., 2009); CPD-0801 has not been tested.   
Basolateral efflux in renal proximal tubule cells is primarily for recovery of 
essential molecules back into circulation.  Basolateral efflux of organic cations is 
not well studied, as many of them are exogenous compounds.  As discussed 
above, most drugs associated with nephrotoxicity are cleared primarily by the 
kidney (Greenberg, 2009).  Therefore, movement of these organic cations back 
into the plasma is not the primary function of renal proximal tubule cells.  
Although both OCTs are capable of bi-directionality, cations are transported 
selectively into the cell down the electrochemical gradient maintained by a 
sodium/potassium pump (Sokol and McKinney, 1990).  Diamidines may be 
substrates for equilibrative nucleoside transporter 1 (ENT1), a bidirectional 
transporter found on the basolateral membrane of epithelia and known to be 
expressed in the kidney (Baldwin et al., 2004; Lu et al., 2004).  ENT1 is believed 
to be involved in purine and pyrimidine nucleoside salvage and regulation 
(Baldwin et al., 2004).  The pyrimidine rings in CPD-0801 in particular could 
make it a suitable substrate for ENT1.   
Apical, or brush border membrane, transport proteins in renal proximal 
tubule cells are responsible for both the reabsorption and secretion of organic 
cations.  Apical efflux transporters are selective with their substrates based on 
lipophilicity (hydrophobicity independent of the cation) and, to a lesser degree, 
three-dimensional structure (Wright et al., 1995; Moe et al., 2008).  Organic  
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Figure 8 Furamidine and CPD-0801 are OCT1 substrates.  Furamidine and 
CPD-0801 (1 μM) uptake into CHO cells was measured after 30 minutes.  CHO 
cells were transfected with mock or OCT1 plasmid.  Diamidines were also given 
to CHO-OCT1 cells with ranitidine (1 mM), an OCT1 inhibitor.  Error bars 
represent the standard deviations of the means of three replicates.  Data 
courtesy of Dr. Xin Ming (Eshelman School of Pharmacy, University of North 
Carolina at Chapel Hill).   
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cation/carnitine transporter-novel 1 and 2 (OCTN1 and OCTN2) are part of the 
same family of transporters as OCT1 and OCT2 (SCL22A).  However, the 
kinetics, tissue distribution and selectivity of OCTN1 make it unlikely to be a 
major contributor to apical organic cation exchange (Wright, 2005).  OCTN2 is 
best known for the substrate carnitine and generally prefers zwitterions as 
substrates (Ohashi et al., 1999).  Significant uptake of triethylamine sulfate (TEA, 
a common probe organic cation) seen in OCTN2 transfected cells (Wu et al., 
1999) suggested that OCTN2 may play a role in apical organic cation efflux.  
However, due to the structural dissimilarities of the OCTN2 substrates to 
diamidines, it is unlikely CPD-0801 and furamidine would be OCTN2 substrates.  
More recently, a transport protein from the multidrug/oligosaccaridyl-
lipid/polysaccharide (MOP) superfamily was found to mediate organic 
cation/proton exchange on the apical membrane of renal proximal tubule cells 
(Ohta et al., 2006).  Multidrug and toxicant (or toxin) extruder (MATE1) has been 
shown to transport 4',6-diamidino-2-phenylindole (DAPI), a diamidine compound 
(Yasujima et al., 2010).  Due to the structural similarities of known MATE1 
substrates to CPD-0801 and furamidine, it seems likely that these diamidines are 
MATE1 substrates.   
Other efflux transporters at the brush boarder membrane include ATP-
binding cassette (ABC) superfamily transport proteins such as multidrug-
resistance associated proteins (MRPs) (Wright and Dantzler, 2004).  While both 
the SLC22A and MOP family transport proteins function on an electrochemical 
gradient, ABC superfamily transport is ATP-dependant (Moe et al., 2008).  
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Additionally, the substrates transported by MRPs are generally anionic or neutral 
and have complex ring structures (Lee and Kim, 2004; Wright and Dantzler, 
2004) suggesting that MRPs are unlikely to transport diamidines.  Another ABC 
family transporter, multidrug resistance transporter (MDR1), also known as P-
glycoprotein (P-gp), is well known for its ability to mediate active secretion of a 
variety of substrates (Lee and Kim, 2004).  MDR1 has been well studied and is 
known for its role in removing xenobiotic compounds from the kidney and liver, 
as well as limiting compound entrance into the gut and brain (Kim, 2002; Lee and 
Kim, 2004).  Interestingly, despite its broad specificity, furamidine is not a 
substrate of MDR1 (Ming et al., 2009).   
Reabsorption involves transport of organic cations from the filtrate, across 
the apical membrane, back into the proximal tubule cells.  Like basolateral efflux 
into plasma, reabsorption is largely responsible for recovery and regulation of 
essential molecules.  Concentrative nucleoside transporter 1 (CNT1) is found on 
the apical membrane of renal proximal tubule cells (Gray et al., 2004; Lu et al., 
2004).  As part of a system involving ENT1 (discussed above), CNT is thought to 
recover pyrimidine nucleosides like adenosine back into circulation (Gray et al., 
2004).  Both ENT1 and CNT1 are known to be involved in the transport of drugs 
in addition to endogenous molecules (Huber-Ruano and Pastor-Anglada, 2009).  
It is currently unknown if any diamidines are substrates for nucleoside 
transporters, but CPD-0801 may be a suitable substrate due to its pyridine rings.   
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Summary 
A safe, effective treatment for both first and second stage HAT is essential 
to improving the quality of life in the conflict ridden regions of sub-Saharan Africa.  
Based on the extensive experience gained from the human clinical trials of 
pafuramidine, a new solution may be available.  CPD-0801 has shown promising 
efficacy as an alternative to melarsoprol and NECT for second stage HAT 
treatment.  However, due to the nephrotoxicity of pafuramidine, it must be 
demonstrated that CPD-0801 is less likely to be toxic.   
Since only six out of 80 subjects experienced this serious side effect, it is 
not immediately practical to replicate the delayed kidney toxicity in an animal 
model, especially since liver toxicity is dose limiting.  Development of a 
pafuramidine-induced delayed rodent nephrotoxicity model is ongoing; however, 
the low incidence of toxicity and limited knowledge of the mechanism present 
significant challenges to development of such a model.  In lieu of a rodent model 
of toxicity, and given the association between kidney accumulation and 
nephrotoxicity with a variety of drugs, the differences in rat kidney accumulation 
and distribution of pafuramidine/furamidine and CPD-0801 will be studied.  It is 
hypothesized that the difference in accumulation between furamidine and CPD-
0801 is a result of differential kidney excretion mechanisms.  Understanding the 
mechanisms responsible for the difference in renal accumulation of CPD-0801 
and pafuramidine/furamidine may well aid in determining the potential risk of 
delayed nephrotoxicity in human clinical trials.   
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Chapter 2:  
Monoclonal Antibodies Detect Metabolism of Anti-
Trypanosomal Compounds
1
 
 
Since current treatments for HAT are not satisfactory, a series of 
diamidine compounds are currently in development.  Pafuramidine, an orally 
bioavailable prodrug, is biotransformed to the active compound furamidine 
(Figure 4), which proved effective in the first stage of disease.  Unfortunately, 
phase III clinical trials of pafuramidine have been halted due to an extended 
phase I study which revealed delayed nephrotoxicity (Pholig et al., 2008; Mdachi 
et al., 2009).  Another diamidine analog, CPD-0801, and its prodrug CPD-0868, 
are currently in development to treat the second stage of HAT (Wenzler et al., 
2009).   
A commonly used method in small molecule drug development is high 
performance liquid chromatography/mass spectroscopy (LC/MS/MS).  While 
effective in the research laboratory, LC/MS/MS cannot easily be implemented in 
the clinics of Africa, where ultimately, the bioefficacy studies will be assessed.  
The large, expensive equipment required to run LC/MS/MS and the expertise 
required to utilize the machine is prohibitive in rural sub-Saharan Africa, where 
HAT patients reside.  Protein-based methodologies, specifically enzyme-linked 
                                            
1
 Goldsmith et al. 2010 adapted with permission from the Journal of Clinical Laboratory Analysis.   
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immunosorbant assays (ELISA), could be utilized to study small molecules.  This 
technique is less expensive and more facile than traditional small molecule 
assays.   
Polyclonal antibodies were originally developed against a pentamidine 
analog (1-[4-amidinophenoxy]-5-[4-aminophenoxy]pentane, ADAMP) for use in 
an inhibitory ELISA (IELISA) (Reisner et al., 2000).  Subsequently, monoclonal 
antibodies (Mabs) were produced against the same antigen to provide a more 
uniform source of high affinity reagents for use in the IELISA.  The availability of 
Mabs directed against diamidines has led to the development of a simple assay 
for diamidines of potential clinical interest.  As demonstrated in this paper, Mab 
based immunoassays can be used to detect CPD-0801 and distinguish it from its 
prodrug both in vitro and in vivo.  This method could be further applied to 
studying the metabolism of new anti-HAT agents and localizing active 
metabolites in tissue.   
Materials and Methods 
Production of Monoclonal Antibodies (Mabs) 
Immunization.  Two-month-old female BALB/c mice (Charles River, 
Raleigh, NC) were immunized with pentamidine-ovalbumin conjugate (0.2 mg/ml 
protein, hapten-carrier ratio of 23) prepared as described by Reisner et al. 
(Reisner et al., 2000).  Antigen was emulsified into Titermax™ adjuvant (CytRx, 
Norcross, GA) according to product instructions.  Primary immunization was 
performed by subcutaneous injection into the upper groin region with adjuvant 
solution containing 100 μg of antigen.  Two further immunizations were 
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performed at two week intervals by intraperitoneal (IP) injection of 100 μg antigen 
diluted in phosphate buffered saline (PBS).  One week after the third 
immunization, plasma was collected from anesthetized animals and screened 
using ELISA methodology as previously described (Reisner et al., 2000) with 
modifications described below. Mice demonstrated titers of 1:800 or greater 
(defined as last dilution demonstrating an optical density (OD) of at least 1.5). A 
final IP boost with 20 μg of antigen was performed five days before fusion. All 
animal protocols were approved by the Institutional Animal Care and Use 
Committee (IACUC) of the School of Veterinary Medicine at North Carolina State 
University where fusions were performed.  Animal experiments were approved by 
the IACUC of the University of North Carolina at Chapel Hill.   
Hybridoma production.  The myeloma cell line, P3-X63-Ag8.653 
(American Type Culture Collection, Rockville, MD), was used as a fusion partner.  
Standard fusion protocols using human African trypanosomiasis selection were 
followed (Kearney, 1979) with the following additions: Balb/c peritoneal feeder 
cell layers were used during initial expansion of selected clones from 96 well and 
during three rounds of cloning by limiting dilution.  During these stages, media 
were also supplemented by addition of low-serum supernatant from P388D1 cells 
(Koren, 1975; Nordan, 1986).  Twelve days after fusion, macroscopic growth was 
present in 86% of wells seeded with 5x104 nucleated spleen cells/well.  Initial 
screening of 800 wells detected significant reactivity (OD > 0.30) in 12% using a 
screening ELISA against a pentamidine derivative; 31 of these were strong (OD 
> 1.00).   
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Immunoassay Design 
Detection of immunoreactivity (ELISA for pentamidine).  An ELISA assay 
for the detection of Mab reactivity toward pentamidine and related molecules was 
established based on prior work (Reisner et al., 2000) using Reacti-Bind ™ 
maleic anhydride activated polystyrene 96 well “strip plates” (Pierce, Rockford, 
IL) sensitized with 1-(4-amidinophenoxy)-5-(4-aminophenoxy)pentane (ADAMP, 
synthesized at UNC Chapel Hill) diluted to 0.01 μg/ml in PBS, pH 7.4 (Sigma, St. 
Louis, MO) (as described in detail  in Reisner et al. (Reisner et al., 2000)).  One 
hundred microliters of appropriate dilutions of animal sera, Mab containing 
supernatant or purified immunoglobulin preparations were made in PBSB (PBS 
with 2% Blotto, 1:5 non-fat dry milk in PBS w/v) and incubated in sensitized and 
blocked wells for 2 hours at 37°C prior to washing and development with goat 
anti-mouse horseradish peroxidase labeled antibody (Jackson ImmunoResearch 
Laboratories Inc, West Grove, PA) diluted 1:20,000 in PBSB.  The color change 
was monitored at 405 nm with a SPECTRAmax 340PC plate reader (Molecular 
Devices, Sunnyvale, CA).  The natural fluorescence of the compounds does not 
interfere with this color change reaction.   
Inhibitory ELISA for the detection of pentamidine-like compounds.  The 
inhibitory ELISA (IELISA, see Figure 9 for a schematic) was carried out as in 
Reisner et al. (Reisner et al., 2000) with the following modifications.  Fifty 
microliters of analyte (“inhibitor”) were mixed with 50 μl of an appropriate dilution 
of Mab (generally 1:100 dilution of monoclonal anti-pentamidine antibody 
1.85.72) in sensitized blocked wells and incubated for two hours at room 
temperature (RT) followed by washing and addition of secondary antibody to the  
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Figure 9 Schematic of Inhibitory ELISA.  (A) The color intensity is inversely 
proportional to antibody binding of the compound of interest due to the inhibitory 
nature of the assay.  The more primary antibody that binds to the compound of 
interest, the lighter the color green that will be observed.  (B) A schematic of 
plate format.  The top row shows what the column is coated with PBS (negative 
control), mouse serum (MS, positive control) or mono-aminopentamidine (shown 
in A as grey circles).  The bottom row demonstrates the appropriate dilutions of 
compound of interest for each row of the plate.   
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wells at RT with Tris Buffered Saline (TBS).  Blank mouse plasma was included 
on each plate as a control for secondary antibody binding, and a vehicle "zero 
dose" control for maximum binding was also included.  Pentamidine-like 
compounds were assayed for immunoreactivity using dilutions from 
approximately 4 nM to 16 μM in DMSO.  Two compounds were tested on each 
plate, one of which had been previously tested and therefore served as a positive 
control.  The assay was replicated four times per compound on each plate for 
two plates, and then repeated with a series of higher concentrations to more fully 
cover the relevant range of concentrations.  The data were manually normalized 
to the “zero dose” DMSO control.  Inhibition curves were plotted (concentration 
versus normalized absorbance at 405 nm) and the EC50 calculated using a 
sigmoidal variable slope dose response curve (Prizm version 4 GraphPad 
Software, Inc., San Diego, CA).   
Metabolite Detection 
Treatment of sandwich-cultured rat hepatocytes (SCRH) with CPD-0868.  
Hepatocytes were isolated from male Wistar rats and seeded onto BioCoatTM 
collagen plates as reported previously (Liu et al., 1999).  Approximately 24 h after 
seeding, cells were overlaid with BD MatrigelTM.  Thereafter, culture medium was 
changed every 24 h.  On day 4, SCRH were incubated with CPD-0868 (10 µM) in 
culture medium.  Media samples were collected at 0.08, 0.17, 0.33, 0.5, 1, 2, 4, 
8, 16, 24 h.  All samples were stored at −20°C until LC/MS/MS analysis.  
Treatment of rats with CPD-0868.  Male Sprague-Dawley rats, were 
administered CPD-0868 (25 mol/kg), formulated as a suspension of 0.1% 
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Tween 80:ethanol (80:20 v/v) by oral gavage (PO).  Blood (0.15 mL) was 
collected from a tail vein at 0.25, 0.5, 0.75, 1, 2, 4, 8, 12, 24 and 48 hr after CPD-
0868 administration.  Plasma was stored at -20°C pending analysis by 
LC/MS/MS.   
Analysis of in vitro and in vivo samples by LC/MS/MS.  Analysis was 
modified from Midgley et al. and Trendler et al. (Trendler, 2000; Midgley et al., 
2007).  For a sample method, see Appendix II.  All data was acquired by the 
ADME Mass Spectrometry Center at UNC Chapel Hill.   
IELISA analysis of in vitro and in vivo samples.  The IELISA was carried 
out for the detection of pentamidine-like compounds as above with modifications.  
In brief, 50 μL of medium or a 5-fold dilution (in TBS with 2% blotto) of rat plasma 
were added to 50 μl of a 1:100 dilution of Mab 1.85.72 in a sensitized blocked 
well and incubated for two hours at RT, followed by washing and addition of 
secondary antibody (as described above).  The data were manually normalized 
to the vehicle “zero dose” control.  A non-parametric correlation test was used to 
compare the LC/MS/MS data and the ELISA data (Prizm version 4 GraphPad).   
Results 
Production and Selection of Monoclonal Antibodies  
Prior work from this laboratory established the technology for the 
production of murine polyclonal antibodies reactive with pentamidine and related 
compounds (Reisner et al., 2000).  Such antibodies show specificity for the 
aromatic amidine group of the immunizing hapten and broad cross-reactivity with 
other dicationic agents having related structures (Figure 10) as detected using  
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Figure 10 Diamidine compounds used for screening 
monoclonal antibodies.   
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an inhibitory enzyme-linked immunosorbant assay (IELISA).  Based on this work, 
monoclonal antibodies (Mabs) were generated to the pentamidine-ovalbumin 
conjugate to be used in developing a Mab based IELISA. Candidate Mab clones 
were screened not only for reactivity with the parent compound (pentamidine), 
but also with 2,5-bis-[4-amidinophenyl]furan (furamidine) and 2,7-
diamidinocarbazole (02DAP092) (Patrick et al., 1999).  CPD-0801 was not 
available in sufficient quantity for use at the time of screening.  Supernatants 
from twelve wells out of 96 (chosen on the basis of titer) were evaluated for 
reactivity against furamidine and 02DAP092 in an IELISA format, and three wells 
were chosen for subcloning through two more selection cycles to monoclonality.  
The three resultant Mabs (clones 1.85.72, 1.93.65 and 4.57.72) all demonstrated 
some degree of reactivity with the target compounds and were of the IgG1 
isotype.  Individual cultures secreted between 100 and 160 μg of immunoglobulin 
per milliliter of medium.  One Mab, 1.85.72, was chosen for detailed study as it 
showed the greatest sensitivity for detection of pentamidine, and also 
demonstrated the greatest degree of cross-reactivity between the three 
diamidines (Figure 11).   
Sensitivity and Specificity of Monoclonal Antibodies 
Assay sensitivity and specificity were evaluated using the previously 
described IELISA format in which ADAMP was covalently coupled to microtiter 
plates.  In this assay, the analyte competing with the “sensitized” well for Mab 
1.85.72 binding, and was measured as an indication of antigenic activity (Table 
5).  EC50 values were determined for assays of the three target compounds 
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Figure 11 Cross-reactivity of different antibodies to the three screening 
compounds.  Immunoassay for diamidine reactivity using pentamidine (■), 
02DAP092 (▲) and furamidine (●) standards diluted in PBS/blotto.  
Vertical bars represent standard deviation.  Lines represent the best fit 
using four parameter, non-linear regression as described in the Materials 
and Methods.  The parameter representing maximal binding was 
estimated and fixed using “0-dose” controls.   
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Compound Matrix EC50 (ng/mL) 95% CI Sensitivity 
Pentamidine 
Serum 0.18 0.15-0.21 >0.1 
Buffer 0.55 0.37-0.82 ND 
02DAP092 
Serum 1.3 1.1-1.5 >0.5 
Buffer 2.9 2.4-3.5 ND 
Furamidine 
Serum 14.5 11.8-17.8 >2.0 
Buffer 15.0 12.9-17.5 ND 
Table 5 IELISA sensitivity.  Immunoassay for comparing pentamidine, 
02DAP092 and furamidine using standards diluted in PBS/blotto or a 1/6 dilution 
of human serum in PBS/blotto.  EC50 calculations were made as described in the 
Materials and Methods.  The data are derived using a four parameter fit.  EC50 is 
the concentration for half maximal inhibition.   
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using either assay buffer or a 1/6 dilution of human serum in buffer as sample 
matrix.  As expected, the assay was most sensitive in detecting pentamidine 
(EC50 in the 0.2-0.6 ng/ml range), less sensitive in detecting 02DAP092 (EC50 of 
1.0-3.0 ng/ml) and least sensitive for furamidine (EC50 about 15.0 ng/ml).  The 
assays for pentamidine and 02DAP092 were slightly more sensitive in the 
presence of diluted serum (details in Table 5).  The assay specificity for the three 
dicationic agents was sufficient for potential use in a clinical setting.  Mabs 
1.93.65 and 4.57.72 (not studied in detail) had EC50 values for pentamidine in 
assay buffer of about 3.0 and 15.0 ng/mL, respectively.  The use of monoclonal 
anti-pentamidine antibodies significantly reduced the assay background 
compared to previous assays that used the polyclonal antibodies.   
Mab 1.85.72 was evaluated for reactivity with bis-amidoxime and 
methylamidoxime prodrug derivatives of furamidine (M2 and pafuramidine 
respectively, Figure 4).  No reactivity was detected with either prodrug when 
tested at 100 ng/ml.  The prodrugs have less than 2% of the immunoreactivity of 
the parent compound, furamidine, suggesting that the Mab can be used to 
monitor prodrug conversion.   
Detection of CPD-0868 and Known Metabolites 
The IELISA was used to evaluate the utility of the Mab based assays in 
detecting the bioconversion of the newly developed prodrug (CPD-0868) to its 
active metabolite (CPD-0801, metabolic pathway shown in Figure 4).  Mab 
1.85.72 reactivity against pafuramidine and its metabolites was assessed (see 
Appendix I).  However, due to extensive contamination of synthesized standards, 
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confidence in the EC50 data was not attained.  The EC50s were used as a basis 
of comparison of prodrug, intermediates and active diamidine (Table 6).  CPD-
0868, M1 and M2 have no significant immunoreactivity.  Both M3 and CPD-0801 
demonstrate substantial immunoreactivity in the assay.  The EC50 for CPD-0801 
is approximately half that of M3, but still approximately 16 times more than 
pentamidine.  M4 could not be tested as it is unstable.   
Monitoring Metabolism of CPD-0868 In Vitro  
After successfully differentiating between CPD-0868 and the active 
diamidine, CPD-0801, the IELISA was utilized to detect CPD-0868 metabolism in 
sandwich-cultured rat hepatocytes (SCRH).  SCRH metabolized CPD-0868 over 
time to CPD-0801.  Metabolism was measured using the gold standard, 
LC/MS/MS, to quantify M3 and CPD-0801, the metabolites known to bind to Mab 
1.85.72 (Figure 12B).  As expected, M3 initially increases rapidly, and CPD-0801 
gradually increases over the 24 hour period.  A similar trend is observed in the 
data acquired by IELISA (Figure 12A).  The non-parametric correlation yields the 
highest spearman coefficient, 0.96, when the LC/MS/MS data for both M3 and 
CPD-0801 are combined in the comparison (Table 7).   
Monitoring Metabolism of CPD-0868 In Vivo  
To evaluate the use of the IELISA for monitoring in vivo bioconversion of 
prodrug, Sprague-Dawley rats were orally treated with CPD-0868.  Metabolism 
was measured using the gold standard technique, LC/MS/MS quantification of 
CPD-0801 (Figure 12D), the only metabolite available for quantification at that 
time, in plasma samples.  CPD-0801 rapidly increases in the first two hours then  
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Compound EC50 (nM) SEM
a of EC50 Binding? 
CPD-0868 >18000 --- negligible 
M1 >16000 --- negligible 
M2 >16000 --- negligible 
M3 123.7 0.3 yes 
M4 unstable 
CPD-0801 65.1 0.3 yes 
Furamidine 17.6 0.02 yes 
Pentamidine 4.07 0.01 yes 
Table 6 EC50 of Mab 1.85.72 binding to CPD-0868 and metabolites.  IELISA 
comparing prodrug (CPD-0868), M1, M2, M3, CPD-0801, furamidine and 
pentamidine standards diluted in TBS/blotto.  Attempts to synthesize M4 failed to 
result in a stable compound for quantification purposes.   
a SEM, standard error of the mean of eight replicates.   
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Figure 12 LC/MS/MS and IELISA detection of CPD-0868 metabolites in vitro and 
in vivo.  (A) IELISA analysis of medium from SCRH treated with CPD-0868.  
Vertical bars show standard deviation of three samples in triplicate.  (B) 
LC/MS/MS quantification of M3 (□) and CPD-0801 (Δ) in medium from SCRH.  
The sum of M3 and CPD-0801 is also shown (●).  Vertical bars show standard 
deviation of three replicates.  (C) IELISA analysis of plasma from rats treated 
with CPD-0868.  Vertical bars show standard deviation of two samples in 
triplicate.  (D) LC/MS/MS quantification of CPD-0801 (●) in plasma from rats 
treated with CPD-0868.  Vertical bars show standard error of two replicates.   
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Comparison 
Spearman 
Coefficient 
SCRH in vitro 
M3 vs. IELISA 0.92* 
CPD-0801 vs. IELISA 0.88* 
M3 + CPD-0801 vs. IELISA 0.96* 
Rats in vivo CPD-0801 vs. IELISA 0.933** 
Table 7 Correlations between IELISA and LC/MS/MS.  Compound names 
indicate the molecule quantified by LC/MS/MS.  * p≤0.003, ** p=0.007 
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decreases through the remainder of the 24 h period.  A similar, but not identical, 
trend is observed in the data acquired by IELISA (Figure 12C).  The presence of 
detectable compounds rapidly increases in the first two hours; however, it does 
not return to the initial value perhaps because the antibody detects M3, active 
diamidine and possibly M4.  The non-parametric correlation yields a Spearman 
coefficient of 0.93.   
Discussion 
Pentamidine has long been used as an anti-trypanosomal compound.  
However, its use is limited as it must be delivered parenterally, has potentially 
serious side effects, and can only treat the first stage of HAT.  For these reasons, 
several other diamidine compounds are in development for treatment of HAT, 
most notably CPD-0801 for treatment of second stage disease.  To avoid 
parenteral dosing, an orally bioavailable prodrug (CPD-0868) was developed, 
which is bioconverted in the liver to the active agent.  Therefore, a method to 
specifically measure the quantity and tissue disposition of active metabolites in 
the presence of prodrug is of importance and may be accomplished using the 
immunoassay for pentamidine-like compounds described here.  Although 
immunoassays would not be expected to have the exact specificity and 
sensitivity of well described LC/MS/MS based assays (Midgley et al., 2007), they 
have the potential advantage of  simplicity and low cost.  
The assay sensitivity for the three Mabs studied was sufficient for potential 
use in a clinical setting.  Mabs 1.93.65 and 4.57.72 (not studied in detail) had 
EC50 values for pentamidine in assay buffer of about 3.0 and 15.0 ng/mL, 
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respectively.  The use of monoclonal anti-pentamidine antibodies significantly 
reduced the assay background compared to previous assays that used the 
polyclonal antibodies.  Mab 1.85.72 was selected for use in all subsequent 
experiments because it most effectively detected furamidine (EC50 of 15 ng/mL).   
We have used the Mab based assay in ongoing studies of the newly 
developed prodrug/drug pair CPD-0868 and CPD-0801 (Wenzler et al., 2009).  
As shown in Table 6, only active diamidine, CPD-0801, and M3 had significant 
immunoreactivity in the Mab based assay.  This suggests that the amidine moiety 
is essential for antibody recognition, and if M4 were tested, the antibody would 
most likely bind to it with a similar affinity to that of M3.  However, there remains 
a 16-fold difference in affinity between CPD-0801 and pentamidine, both of which 
are diamidines; therefore, other compounds would need to be screened to 
ascertain the importance of the central portion of the molecule to antibody 
binding.  It is advantageous that the monoclonal antibody recognizes only those 
CPD-0868-derived compounds that have activity against trypanosomes (Wenzler 
et al., 2009).   
The IELISA can be used to monitor prodrug metabolism to active 
compound(s).  SCRH were treated with CPD-0868.  Medium was monitored for 
M3 and CPD-0801 by LC/MS/MS and the results compared to the medium 
analysis by IELISA (Figure 12).  The two techniques had the strongest 
correlation, as defined by a Spearman coefficient of 0.96, when the LC/MS/MS 
data for M3 and CPD-0801 were summed.  This is not surprising since it has 
been established that the antibody binds both to M3 and active diamidine.   
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Metabolism can be measured in an in vitro system, but for the assay to be 
clinically relevant, the antibody must detect active diamidine compound in a 
plasma matrix.  Rats were orally treated with CPD-0868, and the active diamidine 
was measured in plasma over time by LC/MS/MS.  The gold standard analysis 
was compared to the inhibitory ELISA, resulting in a spearman coefficient of 
0.93.  The correlation is satisfactory for clinical use of the IELISA; however the 
coefficient might be improved by quantification of metabolites such as M3 or 
other, less common derivatives.   
In summary, this immunoassay for diamidine compounds demonstrates 
utility in compound screening, pre-clinical testing and as a clinical test.  The 
assay uses a convenient format, tolerates medium and plasma as a sample 
matrix and has more than sufficient sensitivity to detect clinically relevant (and 
certainly toxic) levels of compound in blood.  The IELISA is simpler and more 
cost-effective then the common small molecule assays, HPLC and LC/MS/MS, 
making it more easily adaptable for use in therapeutic drug monitoring in 
developing countries and other areas without access to specialized equipment, 
locations where HAT is of greatest concern.  Although the current format of this 
assay lends itself primarily to a laboratory research setting, the IELISA could be 
modified to a simple color-change assay for monitoring compound concentrations 
at point-of-care facilities.  A further application of the monoclonal antibody is 
visualization of diamidine compounds in tissue using immunohistochemical 
techniques, providing a convenient and rapid approach to localizing sites of 
compound accumulation.    
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Chapter 3:  
Accumulation, Localization and Mechanism 
 
Current treatments for HAT require parenteral administration due to poor 
bioavailability and are often toxic (Barrett et al., 2007; Kennedy, 2008; Lutje et 
al., 2010; Yun et al., 2010).  Due to these limitations, research has continued for 
alternate and improved drugs.  Furamidine, a pentamidine analog, (Figure 3) 
was shown to be efficacious in a murine model of first stage disease (Wenzler et 
al., 2009).  Since furamidine has very low oral bioavailability, a prodrug approach 
was used to create an oral potential therapeutic.  The amidine moieties were 
modified to create a bis-O-methylamidoxime prodrug of furamidine, termed 
pafuramidine.  Pafuramidine was more than 90% effective and less toxic than 
pentamidine throughout phase II and III clinical trials.  However, further 
development was discontinued due to unforeseen delayed onset acute renal 
insufficiency observed during an expanded phase I safety study (Paine et al., 
2010).  Despite this setback, a second novel pentamidine analog, 2,5-Bis[5-
amidino-2-pyridyl]furan (CPD-0801).  CPD-0801 (Figure 3), is in early pre-clinical 
development for second stage HAT.  CPD-0801 differs structurally from 
furamidine in that pyridine rings replace the phenyl rings.  Although furamidine 
has a lower in vitro IC50 to kill trypanosomes, CPD-0801 has a superior cure rate 
in vivo (Wenzler et al., 2009).  Moreover, because CPD-0801 is curative in the 
second stage mouse model of HAT, it may be capable of penetrating the blood 
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brain barrier.  Given the nephrotoxicity of pafuramidine, the potential renal toxicity 
of CPD-0801 must be addressed if it is to enter human clinical trials.   
Although a rodent model for the delayed nephrotoxicity in humans has not 
yet been developed, there is evidence for a connection between organ 
accumulation and toxicity (Filipski et al., 2009; Tanihara et al., 2009; Quiros et 
al., 2010).  This work describes distinct differences in accumulation and excretion 
of furamidine and CPD-0801 in rat kidney.  In addition, tissue binding and 
transport are explored as potential explanations for the differences observed 
between two structurally similar compounds.   
Methods 
Materials and Chemicals 
Pafuramidine, deuterated pafuramidine, CPD-0868, furamidine, 
deuterated furamidine, CPD-0801, as well as M1, M2 and M3 for both the 
pafuramidine and CPD-0868 series, were a kind gift from Dr. David Boykin 
(Georgia State University, Atlanta, GA) and were synthesized as described 
previously (Francesconi et al., 1999; Ismail et al., 2003; Ismail et al., 2006).  
Additional materials used were as follows: Sprague-Dawley rats (Charles River 
Laboratories, Wilmington, MA); Tween 80, Tris buffered saline (TBS), DMSO, 
Ham‟s F12, sodium carbonate, HEPES, 1-methyl-4-phenylpyridinium (MPP) 
(Sigma Aldrich, St. Louis, MO); ProLong Gold, goat anti-mouse labeled with 
Alexa Fluor 647, zeocin, 4',6-diamidino-2-phenylindole (DAPI) (Invitrogen, 
Carlsbad, CA); streptomycin/penicillin, Hanks‟ balanced salt solution (Gibco, 
Carlsbad, CA); ethanol (Fisher Scientific, Pittsburgh, PA); sterile saline (Hospira, 
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Lake Forest, IL); trifluoroacetic acid (TFA, Acros Organics, Geel, Belgium); FBS 
(PAA Laboratories, Pasching, Austria); hygromycin B (Cellgro by Mediatech, Inc., 
Manassas, VA); and D-glucose (Mallinckrodt Baker Inc., Paris, KY).   
Animal Studies 
All animal studies utilized 8-10 week old, 200-350 g male Sprague-Dawley 
rats.  Animal protocols were approved by the Institutional Animal Use Committee 
of the University of North Carolina at Chapel Hill.   
Oral prodrug administration.  Prodrugs were prepared in 1:9 70% Tween 
80/30% ethanol in water.  Rats were administered 30 μmol/kg pafuramidine or 
CPD-0868 (approximately 0.75 mL of 10 mM stock solution) by oral gavage 
(PO).  At six hours or eight days post administration, rats (N = 3-7 per time point) 
were sacrificed.  Kidneys from the right side were homogenized, diluted 1:3 in 
TBS and analyzed by LC/MS/MS for prodrugs, M1, M2, M3 and diamidine 
metabolites.   
Intravenous active diamidine administration.  Furamidine and CPD-0801 
were prepared in sterile saline (10 μmol/kg); the solutions were heated to 60°C to 
facilitate dissolution.  Rats were administered furamidine or CPD-0801 
(approximately 0.25 mL of 10 mM stock solution) by intravenous infusion (30 s) 
via a femoral vein cannula.  Rats (N = 3-7 per time point) were sacrificed after 3, 
6, 12, 24, 48, 96, 192, or 364 hours.  Kidneys from the right side were harvested, 
homogenized and diluted in TBS (1:3 w/w).  Plasma was obtained serially by tail 
nick (100 μL) from five minutes to eight hours after administration.  The 3, 6, 12 
and 24 h collections were obtained by cardiac puncture (at least two milliliters, on 
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average approximately seven milliliters of blood).  Plasma samples were not 
diluted.  All samples were analyzed by LC/MS/MS as described below.  
Pharmacokinetic parameters were calculated by compartmental modeling using 
WinNonlin v5.0.1 (Pharsight, Mountain View, CA).  Goodness-of-fit was 
evaluated using standard criteria, including visual comparison of observed data 
with predicted concentration-time profiles, residual analysis, Akaike‟s Information 
Criteria, and precision of parameter estimates (CV%).   
Urine collection.  Urine was obtained passively from femoral vein 
cannulated rats in metabolic cages (Nalgene, Rochester, NY).  Animals had at 
least a four day acclimation period before intravenous administration of 
furamidine or CPD-0801 (described above).  Urine was collected at the following 
intervals: 0-3, 3-6, 6-12 and 12-24 h post administration (N = 3-4 per collection 
interval).  Samples were prepared for high performance liquid chromatography 
with fluorescence detection (HPLC-FLD) as described below.   
LC/MS/MS and HPLC-FLD analysis.  This protocol was adapted from 
Midgley et al. 2007 (Midgley et al., 2007); a more detailed description of all 
analytical protocols can be found in Appendix II.  In summary, all kidney 
homogenates and plasma collections were analyzed by LC/MS/MS.  In brief, 25 
μL of plasma or kidney homogenate were added to 25 μL DMSO, mixed and 
precipitated with 1:7 water:methanol containing 0.1% trifluoroacetic acid (TFA).  
Calibration standards were prepared in DMSO and added 1:1 to matrix (kidney 
homogenate or plasma).  Prodrug, M1, M2, M3 and active diamidine for both the 
pafuramidine and CPD-0868 series (Figure 4) were quantified using d6-
68 
pafuramidine (prodrug, M1, M2) or d6-furamidine (M3, diamidine) as the internal 
standard.  The lower limit of quantification was 10 nM.  There are no 
quantification standards for M4 or glucuronidated metabolites for either series, 
but they were monitored using LC/MS/MS.  Urine samples were prepared with no 
internal standard due to lack of suitable candidates.  The internal standards 
available overlapped sample peaks or were obscured by endogenous urinary 
peaks.  HPLC-FLD (Agilent, Santa Clara, CA) was used to quantify compound in 
urine with an excitation of 359 nm and an emission of 462 nm.  The lower limit of 
detection was 130 nM.  Samples were analyzed by the ADME Mass 
Spectrometry Center at UNC Chapel Hill.   
Imaging 
Immunohistochemical staining.  The kidneys from the left side were taken 
from animal studies (see above) and fixed in neutral buffered formalin for 3-8 
days.  Samples were embedded in paraffin and sectioned longitudinally.  
Immunohistochemical staining was carried out in the Bond Autostainer (Leica 
Microsystems Inc., Norwell, MA). Briefly, slides were dewaxed in Bond Dewax 
solution and hydrated in Bond Wash solution. Antigen retrieval was performed for 
20 min at 100ºC in Bond-Epitope Retrieval solution 1, pH 6.0 (AR9961).  Slides 
were incubated with primary antibody 1.85.72 (Reisner et al., 2000; Goldsmith et 
al., 2010) (1:400) for 30 min. Detection was performed using the Bond Polymer 
Refine Detection System (DS9800). Stained slides were dehydrated, mounted 
and imaged using an Aperio slide scanner (Aperio Technologies, Vista, CA).   
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Fluorescence imaging.  Furamidine and CPD-0801 have fluorescence 
properties similar to DAPI stain, also a diamidine (Mathis et al., 2006; Ward et al., 
2009).  Inherent fluorescence of the compound in paraffin embedded whole 
kidney sections was imaged by an Ariol slide scanner (Applied Imaging, now 
Leica Microsystems Inc., Wetzlar, Germany) using a DAPI filter.  Magnified 
images of the inherent fluorescence of the compound were taken of slides 
prepared as above, but with buffer alone during the primary incubation and 
mounting with ProLong Gold after the secondary incubation.  
Immunofluorescence (IF) was not possible because the monoclonal antibody 
affinity does not seem sufficient to bind to all furamidine contained in the tissue.  
IF used monoclonal antibody 1.85.72 (Goldsmith et al., 2010) as the primary 
antibody and goat anti-mouse labeled with Alexa Fluor 647 as the secondary 
antibody (Figure 13).  After attempting IF, in addition to the fluorescence 
generated by the antibody staining, significant inherent fluorescence of the 
compound was still visible.  Although the antibody and inherent fluorescence are 
in the same cells, they do not co-localize.  Since inherent fluorescence signal 
was visible in the no-primary antibody control, lack of co-localization of the two 
signals suggested antibody binding-dependent quenching.  Fluorescent images 
of kidney cells were obtained using a Zeiss D710 laser scanning confocal (Carl 
Zeiss Inc., Maple Grove, MN), with excitation at 405 nm with emission 410 nm 
long pass for inherent florescence and excitation at 633 nm with emission 638 to 
755 nm for Alexa Fluor 647.   
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Figure 13 Magnification of the outer stripe in a furamidine treated rat kidney 
stained with anti-pentamidine antibody.  Furamidine was administered IV and the 
kidney was harvested and fixed after four days.  The inherent fluorescence of the 
compound (blue) and the anti-pentamidine stain (pink) are both found in the 
proximal tubules of the outer stripe (solid arrow), but not the distal tubules 
(broken arrow).   
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The above procedures were conducted in conjunction with the 
Translational Pathology Laboratory, the Lineberger Animal Histopathology Core 
and Microscopy Services Laboratory at UNC-CH.  All color images were 
enhanced using Adobe Photoshop (version 7.0, Adobe Systems Incorporated, 
San Jose, CA) to mimic what was observed through the eyepiece.  Gray scale 
fluorescent images were not manipulated; exposure and gain were equivalent for 
each compound, therefore intensity of the same compound can be compared.   
Determination of Unbound Fraction 
A rapid equilibrium dialysis kit (Pierce, Rockford, IL) was used to measure 
the unbound fractions of furamidine and CPD-0801.  Kidney homogenate 
(prepared as described above) or plasma was mixed with furamidine or CPD-
0801 to yield a final concentration of 2 or 20 μM.  The mixture (200 μL) was 
placed in the matrix chamber, and TBS (350 μL) was added to the buffer 
chamber.  All samples were incubated for six hours at 37°C (as measured in the 
teflon block) on a thermomixer (300 rpm or lowest setting) (Eppendorf AG, 
Hamburg, Germany).  Preliminary studies established that these conditions 
achieve equilibrium.  The contents of each chamber were stored at 4°C for <48 h 
and were prepared for LC/MS/MS analysis.  An aliquot (25 μL) from the matrix 
chamber (or blank matrix) was mixed with 25 μL of buffer (or buffer chamber), 
and samples were prepared as described above for LC/MS/MS analysis.  
Standard curves were prepared with 1:1 mixture of matrix (buffer, kidney 
homogenate or plasma) and buffer.   
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Uptake of Diamidines into hMATE1-CHO Cells and Rat Kidney Slices 
hMATE1 uptake study.  Multidrug and toxin extruder 1 (MATE1) is an 
organic cation transporter expressed in the apical membrane of renal proximal 
tubule cells (Otsuka et al., 2005; Ohta et al., 2006).  FlpIn CHO and FlpIn CHO-
hMATE1 cells were generated by the laboratory of Dr. Stephen Wright 
(Department of Physiology, University of Arizona, Tucson, AZ) using the Flp-In 
mammalian transfection system (Invitrogen, Carlsbad, CA) (Astorga et al., 2010).  
Cell lines were cultured in 24-well plates using complete Ham‟s F12 medium with 
Kaighn‟s modification (pH 7.2): Ham‟s F12, 150 mM sodium carbonate, 10% 
FBS, 100 μg/mL streptomycin, 100 U/mL penicillin and 100 μg/mL zeocin (FlpIn 
CHO) or hygromycin B (FlpIn CHO-hMATE1).  The cells were used at 95-100% 
confluence for uptake studies.  Cells were preincubated for 30 min at 37°C in 
transport buffer: Hanks‟ balanced salt solution with 25 mM D-glucose and 10 mM 
HEPES, pH 7.2 (Ming et al., 2009).  Experiments were initiated by addition of 1 
μM furamidine or CPD-0801 in transport buffer.  After 2, 5, 20 or 30 min, uptake 
was terminated by washing three times with cold transport buffer (approximately 
1 mL) and adding 15% methanol in water with 0.1% TFA.  Sample (25 μL) was 
added to 25 μL water and prepared for HPLC-FLD as described above.   
Based on previous studies (Yasujima et al., 2010), transfection control 
(mock) cells were grown in a 12-well dish from the same passage as the cells 
used for uptake studies.  Cells were pre-incubated for 30 min at 37°C in transport 
buffer.  DAPI (1 μM) in transport buffer was added and fluorescence monitored 
on a plate reader (BMG Labtech, Offenburg, Germany) at 37°C every minute for 
60 min (N=3).   
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Uptake by rat kidney slices.  Kidney slices were prepared as described 
previously (Cross and Taggart, 1950; Berndt, 1976).  Slices (N=3) in Cross-
Taggart buffer were exposed to 1 μM furamidine or CPD-0801 with or without 
200 μM 1-methyl-4-phenylpyridinium (MPP), a potent inhibitor of organic cation 
transport (Cross and Taggart, 1950; Crljen et al., 2005).  After one hour at room 
temperature, images were taken on a Zeiss D710 laser scanning confocal using 
a 405 nM excitation and 410 nm long pass emission.  Slices were then frozen on 
dry ice, weighed, homogenized and prepared for LC/MS/MS as described for 
kidney homogenate.   
Results 
Active Diamidine Accumulation after Prodrug Treatment 
The concentrations in the kidney of metabolites generated from 
pafuramidine were compared to determine which were potential candidates for 
inducing delayed nephrotoxicity.  Pafuramidine, M3, and furamidine (Figure 4) 
were detected in kidney homogenate six hours after oral administration of 
prodrug, but only furamidine was detected in kidney homogenate after eight days 
(Table 8).  Six hours after administration of CPD-0868, the prodrug of CPD-0801, 
the metabolites M3, M4 and CPD-0801 were detectable in kidney homogenate.  
After eight days, only CPD-0801 was detectable.  M4 of both prodrugs was 
detected at six hours but could not be quantified due to lack of a stable standard.  
Furamidine was reported previously to undergo glucuronidation (Zhou et al., 
2004), but such metabolites were not detected in these experiments.  The 
concentration of furamidine was higher than CPD-0801 in rat kidney homogenate  
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Pafuramidine CPD-0868 
nmol/g of 
kidney 
6 h 8 d 6 h 8 d 
Prodrug 0.7 (0.2) -- -- -- 
M1 -- -- -- -- 
M2 -- -- -- -- 
M3 7 (2) -- 0.6 (0.4) -- 
Active 
Diamidine 
21 (5) 20 (2) 3 (2) 0.5 (0.3)* 
Table 8 Amount of metabolites measured in rat kidney at six hours and eight 
days post prodrug administration (30 μmol/kg PO).  Values are means (SDs) of 
3-7 rats.  „–„ indicates that compound was below limit of detection (2.5 nM)  by 
LC/MS/MS.  
* p < 0.04 compared to six hours by Student‟s t-test  
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at both six hours (seven-fold) and eight days (40-fold).  There was a significant 
decrease in CPD-0801 concentrations from six hours to eight days; however, a 
decrease for furamidine was not observed over the same time period.  For all 
further experiments, the active diamidines, furamidine and CPD-0801, were 
administered directly, instead of using the prodrugs, to exclude any differences in 
prodrug metabolism that may lead to variations in plasma and tissue exposure of 
the diamidines.   
Pharmacokinetics of CPD-0801 and Furamidine in Plasma and Kidney 
The pharmacokinetics of the two active diamidines in plasma and kidney 
were evaluated after a single intravenous infusion of furamidine or CPD-0801 
(Table 9).  Plasma concentration-time profiles suggested that both compounds 
declined in a bi-exponential fashion up to eight hours, then continued to decline 
over the next 16 h, after which the compounds were not detectable (Figure 14A).  
Furamidine and CPD-0801 levels in kidney declined in a mono-exponential and 
bi-exponential fashion, respectively (Figure 14B).  Both compounds were 
detectable in kidney 16 days post-administration (Figure 14Error! Reference 
source not found.B).  The terminal half-life for both CPD-0801 and furamidine 
was approximately seven days.  Plasma exposure to CPD-801 (area under the 
curve, AUC) was approximately twice that of furamidine.  Kidney exposure to 
CPD-0801 was 14 times less than furamidine.   
Localization within Kidney  
Caution must be exercised in relying on fluorescence to predict drug 
localization and concentrations.  Both furamidine and CPD-0801 are fluorescent,  
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Figure 14 Concentration-time profiles of active diamidines in plasma and kidney 
of rats.  Furamidine (■) or CPD-0801 (▲) was administered by intravenous 
infusion (10 μg/kg over 30 s).  (A) Plasma was collected serially from zero to 
eight hours and by terminal bleed at 12 h and 24 h, and analyzed by LC/MS/MS.  
(B) Kidneys were harvested, homogenized and analyzed by LC/MS/MS. 
Nanomoles per gram of kidney tissue is equivalent to μM, assuming 1 g = 1 mL.  
Symbols and error bars represent means and standard deviations, respectively, 
of 3-7 rats.  The compounds are different from each other and over time in 
kidney homogenate with p < 0.0001 by 2-way ANOVA.  
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Furamidine CPD-0801 
Plasma 
Cmax (μM) 6.7 10 
AUC0-∞ (μmol*h/L) 2.4 4.1 
Terminal t1/2 (h)* 0.9 1.8 
Cltotal (mL/min) 26 16 
Kidney 
Cmax (μM) 14 5.4 
AUC0-∞ (μmol*h/L) 1.4*10
4 1.0*103 
Initial t1/2 (h) -- 11 
Terminal t1/2 (d) 6.9 7.1 
fK (%) 4.6 ± 0.4 0.9 ± 0.4 
Urine 
fe (%) 0.7 ± 0.2 2.5 ± 0.6 
Clrenal (mL/min) 0.12 0.33 
frenal (%) 4.8 ± 0.4 1.5 ± 0.4 
Table 9 Pharmacokinetics of furamidine and CPD-0801 in rats administered 10 
μmol/kg of furamidine or CPD-0801 intravenously.   
*: calculated with time points from zero to eight hours.   
Cmax: maximum concentration 
AUC0-∞: area under the curve from time zero to infinite time 
t1/2: half-life 
Cltotal: total clearance (measured dose)/(plasma AUC0-∞).   
fK: average percent of dose in the kidney from 0 to 24 h.   
fe: percent of dose in urine after 24 h.     
Clrenal: renal clearance (total amount recovered in the urine)/(plasma AUC0-∞).   
frenal: percent of dose in the renal system (fK+fe) for the first 24 h.   
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but they quench upon binding to DNA (Mathis et al., 2007).  Therefore, only 
location, not intensity, should be compared between furamidine and CPD-0801, 
which is one reason why an antibody was used for many experiments.  
Additionally, the antibody was used in conjunction with the inherent fluorescence 
of the compounds to confirm the validity of the imaging results.   
Using an antibody specific for the amidine moiety (Goldsmith et al., 2010), 
a distinct pattern of diamidine disposition was visible 24 h after pafuramidine or 
furamidine administration as detected (Figure 15).  The brown-staining band 
indicated that furamidine was located in the outer stripe of the outer medulla 
(hereafter designated the outer stripe), specifically, in the straight proximal tubule 
cells.  Conversely, very little CPD-0801 was visible in the kidneys of rats treated 
with CPD-0868 or CPD-0801.  Diamidine disposition in the kidney at the 24 h 
time point was similar when administering prodrug orally or diamidine 
intravenously.   
Figure 16 shows that compound localization changed over time.  
Immunolocalization of compound (in brown) was consistent with the inherent 
fluorescence (Mathis et al., 2006; Ward et al., 2009) of the compound (in green) 
at low magnification. After six hours, furamidine and CPD-0801 were visible in 
both the cortex and outer stripe.  By 24 h, specific localization of furamidine to 
the outer stripe remained visible, while CPD-0801 was no longer visible.  The 
most demarcated and clear localization of furamidine to the outer stripe was 
visible at eight days.  By 16 days, furamidine seemed to be in fewer cells, but 
was still observable in the outer stripe.   
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Figure 15 Localization of active diamidines in rat kidney.  Rats were 
administered the prodrugs, pafuramidine or CPD-0868, by oral gavage (30 
μmol/kg); active diamidines, furamidine or CPD-0801, by intravenous infusion (10 
μmol/kg); or vehicle (saline) and sacrificed one day post-administration.  The left 
kidney was removed and fixed in neutral buffered formalin for no more than six 
days.  Sections were stained with an anti-pentamidine antibody (brown) to 
visualize diamidine by immunohistochemistry (blue counterstain).  Lower images 
are magnifications of the outer stripe of the outer medulla from the corresponding 
scans.  
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Figure 16 Visualization of diamidines in rat kidney over time.  Rats were 
administered furamidine or CPD-0801 by intravenous infusion (10 μmol/kg over 
30 s) and sacrificed between six hours and eight days post-administration.  
Paraffin-embedded sections (left panels, compound in green) were visualized for 
each diamidine by UV excitation.  De-paraffinized sections (right panels, 
compound in brown) were stained for diamidine by immunohistochemistry.  
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Confocal microscopy was used to visualize sub-cellular localization of the 
inherent fluorescence of the diamidines (Figure 17).  Six hours after a single 
intravenous dose, furamidine and CPD-0801 were visible in the outer stripe.  
Only furamidine was localized within a sub-cellular structure in convoluted 
proximal tubules in the cortex characterized by a spherical appearance, possibly 
phagolysosomes (Haschek et al., 2010).  Eight days later, furamidine was clearly 
visible in the proximal tubule cells of the outer stripe.  Using the fluorescent 
signal, a punctate structure in the nucleus was visible.  Cytoplasmic fluorescence 
was diffuse and contained small concentrated motes.  Eight days after 
administration of CPD-0801, fluorescence was not visible.   
Renal Elimination of Diamidines 
Consistent with previous data (Midgley et al., 2007), less furamidine 
accumulated in the urine after 24 h (0.7% of the dose) as compared to the 
amount measured in the kidney homogenate (4.6% of the dose) (Table 9).  The 
first 24 h after intravenous administration of CPD-0801 included the rapid initial 
phase of renal elimination, as observed with the kidney accumulation data, and 
the corresponding increase in urine accumulation (2.5% of dose) (Figure 18).  
Although there was less CPD-0801 in the kidney than furamidine, more CPD-
0801 accumulated in the urine than furamidine.   
Tissue Binding 
The unbound fractions of furamidine and CPD-0801 were measured in 
plasma and kidney homogenates (Table 10).  The higher concentration of 20 μM 
was selected to emulate the amount of compound recovered from tissue shortly
   
Figure 17 Magnified images of diamidine in rat kidney.  Rats were administered furamidine or CPD-0801 by intravenous 
infusion (10 μmol/kg over 30 s) and sacrificed six hours or eight days post-administration.  Paraffin embedded slides were 
treated with a staining protocol for maximal visualization of the inherent fluorescence of diamidine compound.  Laser 
scanning confocal (excitation 405 nm) was used to show magnified images of the cortex and outer stripe of the outer 
medulla (outer stripe).  All images are representative.  White bars represent 10 μm.  
8
2
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Figure 18 Comparison of kidney and urine diamidine concentrations for 24 hours 
post administration.  Rats were administered furamidine (left) or CPD-0801 (right) 
by intravenous infusion (10 μmol/kg over 30 s).  Kidneys (checkered) were 
harvested, homogenized and analyzed by LC/MS/MS. Urine (solid) was taken 
passively in the first 24 hours post-dose and analyzed by HPLC.  N=3-4, error 
bars represent standard deviation of the means.  
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Tissue Concentration 
Furamidine 
% unbound 
CPD-0801 
% unbound 
rat plasma 20 μM 11.6 (0.5)b 46 (3)* 
human plasma 20 μM 16 (2) 57 (1)* 
rat kidney 20 μMa 0.289 (0.004) 3.68 (0.06)* 
rat kidney 2 μMa < 0.4 3.2 (0.3)* 
human kidney 20 μMa 0.37 (0.02) 3.5 (0.5)* 
human kidney 2 μMa < 0.4 1.67 (0.05)* 
Table 10 Percent unbound diamidine in kidney homogenate or plasma.  Values 
are means (standard deviations) of three (rat) or four (human) replicates.  < 0.4 
indicates that the compound was below limit of quantification (2.5 nM) on the 
buffer side in all samples.   
a kidney homogenate (1:3 ratio of kidney to TBS) 
* p<0.007 by Student‟s t-test compared to furamidine 
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after dosing; the lower concentration of 2 μM reflected concentrations after long-
term sequestration.  The unbound fraction of CPD-0801 (approximately 19% 
unbound on average) was consistently higher than that of furamidine 
(approximately 5% unbound on average), by approximately three to 12 fold.   
Transport of CPD-0801 and Furamidine in Rat Kidney 
Multidrug and toxicant extrusion protein 1 (MATE1) is a transport protein 
expressed in the brush-border (apical) membrane of proximal tubule cells and is 
known to play an important role in efflux of cationic compounds into the filtrate 
(Ohta et al., 2006; Ohta et al., 2009).  Both furamidine and CPD-0801 appeared 
to be substrates for hMATE1 in transfected Chinese hamster ovary (CHO) cells 
(Figure 19).  DAPI (a positive control substrate) (Yasujima et al., 2010) was used 
to confirm transfection and functionality of the transporter.  High dose MPP, a 
broad spectrum organic cation transport inhibitor, confirmed that diamidine 
uptake was carrier-mediated.  Blockade of hMATE1 with MPP at an inhibitory 
concentration (200 μM) (Ohta et al., 2009) caused a 30% and 70% reduction in 
furamidine and CPD-0801 uptake, respectively.  Inhibition of hMATE1 activity 
was not complete at this concentration of MPP, and there was a significant 
difference in the efficiency of inhibition of the two diamidines (Figure 19).   
After investigating the apical transporter MATE1, basolateral transport was 
explored via a kidney slice experiment.  MPP, at 200 μM, is a known inhibitor of 
OCT1 and OCT2, both of which have been reported to transport diamidines 
between blood and the basolateral side of proximal tubule cells (Ming et al., 
2009).  Analysis was done by laser scanning confocal microscopy data  
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Figure 19 Uptake study in CHO-hMATE1 and CHO control cells.  Furamidine 
and CPD-0801 were added to cells (1 μM).  Uptake over time (top) was 
measured in CHO-hMATE1 (■) and CHO control (●) cells by HPLC-FLD and 
normalized to protein concentration.  Error bars represent standard deviation of 
five replicates.  A fluorescence assay was used to confirm the hMATE1 
transfection (■) with DAPI (bottom left); both mock transfected cells (●) and 
media with no cells (▼) were used as negative controls.  Confirmation of 
hMATE1 transport (bottom right) was done by using 200 μM MPP (checkered 
bars) and measuring uptake after a 30 minute incubation.  Error bars represent 
the standard deviation of the means of four replicates.  * p<0.0005 as compared 
to control by Student‟s t-test.  
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(Figure 20A) and LC/MS/MS (Figure 20B).  LC/MS/MS showed that CPD-0801 
basolateral uptake was 85% higher in rat kidney slices than furamidine after one 
hour of incubation.  CPD-0801 uptake in the presence of MPP remained 
unchanged, whereas furamidine uptake surpassed that of CPD-0801 by 20%, 
although this was not statistically significant.  Confocal microscopy demonstrated 
that less furamidine signal was observed without MPP treatment.  CPD-0801 
signal seemed unchanged under both conditions (with and without MPP).   
Discussion 
Development of new therapeutics for human African trypanosomiasis is 
essential due to the problems associated with current therapies, including 
difficulty in delivery of the drugs, cost of treatments and drug toxicity.  CPD-0801 
is a promising new diamidine candidate that is one of the few molecules active 
against a rodent model of second stage HAT.  However, because of structural 
similarities with furamidine, CPD-0801 may also possess delayed renal toxicity 
like that observed in the pafuramidine expanded phase I safety study.   
The present experiments focused on pharmacokinetics, renal 
accumulation, renal elimination, renal localization, proximal tubule transport and 
tissue binding.  The initial experiment was to determine which metabolite(s) of 
pafuramidine were most likely the causative agent(s) for the delayed 
nephrotoxicity in humans.  It seems that furamidine was the most logical toxic 
agent because eight days after administration of pafuramidine orally, only 
furamidine was detected in the kidney (Table 8).   
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Figure 20 Uptake of diamidines in rat kidney slices.  Furamidine and CPD-0801 
(1 μM) were added to kidney slices with and without MPP (200 μM).  Uptake 
over time was assessed by fluorescent microscopy (A) and by LC/MS/MS (B).  
Error bars represent standard deviation of the means of three replicates.  * 
p<0.05 as compared to control by Student t-test.  
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Given their different methods of administration, pafuramidine, a bis-O-
methylamidoxime prodrug, administered orally, cannot be compared directly to 
CPD-0801, the diamidine currently in development, administered intravenously.  
However, like furamidine, only CPD-0801 is present in the kidney for prolonged 
periods after prodrug administration (Table 8).  Additionally, furamidine and 
pafuramidine, as well as CPD-0801 and CPD-0868, have a similar staining 
pattern by IHC (Figure 15).  Because the differences in kidney localization and 
accumulation are similar after administration of prodrugs or active diamidine, the 
two active diamidines were directly compared in rats independent of the prodrugs 
and their intermediate metabolites.   
Plasma exposure (as measured by AUC) of diamidines theoretically 
correlates with efficacy against the trypanosomes in vivo.  CPD-0801 had twice 
the plasma exposure of furamidine, which may explain why it was more effective 
in the first stage mouse model than furamidine (Wenzler et al., 2009) (Figure 
14).  Additionally, the high total clearance of both diamidines is likely reflective of 
their rapid tissue sequestration.  Kidney exposure may correlate with potential 
nephrotoxicity since the delayed nephrotoxicity was only observed at an 
extended dosing regimen for pafuramidine in humans (Paine et al., 2010).  CPD-
0801 had 14 times less kidney exposure than furamidine, which may indicate that 
CPD-0801 has a lower risk for nephrotoxicity than furamidine.   
In addition to differences in overall kidney exposure and localization, CPD-
0801 had a rapid initial decrease in kidney concentration that was not observed 
with furamidine.  The decrease in CPD-0801 concentration in the kidney 
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correlated with an increase in urine accumulation (2.5% of dose) (Figure 18), 
compared to very little urine accumulation of furamidine (0.7% of dose).  The 
renal clearance of both compounds was at least 10 times lower than glomerular 
filtration rate (approximately 3 mL/min) indicating that both furamidine and CPD-
0801 undergo net reabsorption (Table 9).   
To investigate mechanisms underlying the differences in CPD-0801 and 
furamidine accumulation and excretion in the kidney, both immunohistochemical 
staining and fluorescence imaging were employed.  In one of the five subjects 
who experienced nephrotoxicity (only two were biopsied), pafuramidine 
nephrotoxicity seemed to be located primarily in the tubules at the border 
between the cortex and medulla (Olson, 2010).  Both furamidine and CPD-0801 
initially localized to the cortex and the outer stripe of the outer medulla (Figure 
16).  However, by eight days furamidine was markedly localized to the outer 
stripe, rather than the cortex, and CPD-0801 was no longer visible, consistent 
with the LC/MS/MS data and the expectations based on the biopsy pathology.  
These data further support furamidine as the most likely cause of pafuramidine-
induced delayed nephrotoxicity, and CPD-0801 as less likely to be nephrotoxic.   
As shown by confocal microscopy, diamidines accumulated in proximal 
tubule cells, where they are associated with specific subcellular structures.  Both 
compounds were associated with small, irregularly shaped subcellular structures 
visible in the cytoplasm which may have been mitochondria or phagolysosomes 
(Figure 17).  Localization to the nucleus and possibly mitochondria suggest 
potential mechanisms of toxicity.  A more sensitive detection technique, such as 
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immuno-transmission electron microscopy, could aid in more fully understanding 
the implications of subcellular accumulation.  The presence of CPD-0801 and 
furamidine in the proximal tubules suggests that organic cation transporters may 
be involved in diamidine accumulation in the kidney.   
Both drugs undergo net renal reabsorption.  Transport across the renal 
tubular epithelium requires at least two transport proteins: one on the luminal 
membrane, and one on the basolateral membrane.  Since CPD-0801 and 
furamidine are both dicationic, they must utilize specific transport proteins to 
move into and out of proximal tubule cells.  One such transporter, MATE1, could 
be responsible for diamidine efflux from the proximal tubule cells into the urine 
since both drugs are specifically transported in hMATE1-transfected cells (Figure 
19).  This study does not stipulate whether furamidine or CPD-0801 is a better 
substrate for hMATE1, although the differences in uptake upon treatment with 
MPP suggest both diamidines do not have the same affinity.  However, because 
furamidine and CPD-0801 would be capable of exiting a proximal tubule cell via 
MATE1, apical transport is likely not responsible for the differences in diamidine 
elimination from the kidney.  Additionally, MATE1 is known to be unidirectional in 
the proximal tubules due to the pH gradient (Ohta et al., 2006) so these data do 
not explain how diamidines are reabsorbed from the filtrate.  Further studies are 
needed to fully elucidate the transport proteins involved in reabsorption.   
On the basolateral membrane of proximal tubule cells, a number of 
organic cation transporters are expressed that may be involved in the uptake of 
CPD-0801 and furamidine into proximal tubule cells, such as OCT1 and OCT2.  
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Kidney slices are a convenient technique used to assess basolateral transport 
because the lumens of the tubules are closed (Crljen et al., 2005).  The current 
kidney slice experiment demonstrated that both drugs were taken up, but that 
treatment with MPP, which was expected to reduce uptake, increased furamidine 
uptake, suggesting that an unknown basolateral transporter may be involved 
(Figure 20).  Also unexpected, CPD-0801 uptake was unchanged in the 
presence of MPP.  Although previous studies showed that both furamidine (Ming 
et al., 2009) and CPD-0801 (Xin Ming, unpublished work) are substrates for 
OCT1 and OCT2, this work indicated that OCT1/2 are not necessary for 
furamidine or CPD-0801 uptake into renal cells.  Further studies are needed to 
understand fully the basolateral mechanism responsible for transport of 
diamidines in the kidney slice.  Nevertheless, it seems that both CPD-0801 and 
furamidine can enter and exit renal proximal tubule cells using transport proteins.  
Therefore, while specific uptake into proximal tubule cells may explain the 
localization of diamidines, it does not account for the differences in accumulation 
and excretion.   
An alternative explanation for the low kidney accumulation of CPD-0801 
compared to furamidine may be differential tissue binding as seen previously in 
the liver (Yan et al., 2011).  Since only unbound diamidines can be transported 
out of a proximal tubule cell, low unbound fraction would lead to low renal 
transport and increased tissue accumulation.  More furamidine accumulated in 
the kidney than CPD-0801, but because the unbound fraction of CPD-0801 in rat 
kidney is 10 times the unbound fraction of furamidine, there is effectively five 
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times the amount of free CPD-0801 than furamidine in renal proximal tubule 
cells.  Tissue binding is a probable explanation for the differences in renal 
accumulation and elimination of CPD-0801 and furamidine.   
A combination of pharmacokinetic profiling, imaging and in vitro studies 
has shown that CPD-0801 has lower renal exposure than furamidine in a rat 
model.  The present work in rats, in conjunction with ongoing studies, suggests 
that CPD-0801 is less likely than furamidine to be nephrotoxic in humans.  The 
substitution of the two phenyl moieties by two pyridine rings in CPD-0801 
apparently allows the compound to move more easily into and out of tissues than 
furamidine and be less likely to bind intracellular binding sites for prolonged 
periods.  Based on the current results, it may be possible to assess the potential 
nephrotoxicity of diamidines.  The data indicate that tissue binding could be used 
to design and select compounds with lower tissue binding in hopes of driving 
synthesis during lead selection and optimization towards compounds with an 
improved safety profile.  In addition, urine accumulation could be used potentially 
to predict relative tissue concentrations in human clinical trials.  These data 
suggest that CPD-0801 has a more favorable profile then furamidine, and given 
its superior efficacy in first and second stage HAT preclinical models, CPD-0801 
is deserving of further development.   
  
94 
References 
Astorga B, Hook L and Wright S (2010) Multidrug and Toxin Extrusion's (MATE) 
Role in Renal Organic Cation Secretion. The FASEB Journal 24:Abstract 
# 1025.1012. 
Barrett MP, Boykin DW, Brun R and Tidwell RR (2007) Human African 
trypanosomiasis: pharmacological re-engagement with a neglected 
disease. Br J Pharmacol 152:1155-1171. 
Berndt WO (1976) Use of the tissue slice technique for evaluation of renal 
transport processes. Environ Health Perspect 15:73-88. 
Crljen V, Sabolic I, Susac J, Appenroth D, Herak-Kramberger CM, Ljubojevic M, 
Anzai N, Antolovic R, Burckhardt G, Fleck C and Sabolic I (2005) 
Immunocytochemical characterization of the incubated rat renal cortical 
slices. Pflugers Arch 450:269-279. 
Cross RJ and Taggart JV (1950) Renal tubular transport: accumulation of p-
aminohippurate by rabbit kidney slices. Am J Physiol 161:181-190. 
Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH and Sparreboom A 
(2009) Contribution of organic cation transporter 2 (OCT2) to cisplatin-
induced nephrotoxicity. Clin Pharmacol Ther 86:396-402. 
Francesconi I, Wilson WD, Tanious FA, Hall JE, Bender BC, Tidwell RR, 
McCurdy D and Boykin DW (1999) 2,4-Diphenyl furan diamidines as novel 
anti-Pneumocystis carinii pneumonia agents. J Med Chem 42:2260-2265. 
Generaux C (2010) Effects of Parasitic Infection on the Pharmacokinetics and 
Disposition of Pentamidine Analogs, in Eshelman School of Pharmacy, 
University of North Carolina at Chapel Hill, Chapel Hill. 
Goldsmith RB, Gray DR, Yan Z, Generaux CN, Tidwell RR and Reisner HM 
(2010) Application of monoclonal antibodies to measure metabolism of an 
anti-trypanosomal compound in vitro and in vivo. J Clin Lab Anal 24:187-
194. 
Haschek WM, Wallig MA and Rousseaux C (2010) Kidney and Lower Urinary 
Tract, in Fundamentals of Toxicologic Pathology pp 266-267, Academic 
Press, London. 
Ismail MA, Arafa RK, Brun R, Wenzler T, Miao Y, Wilson WD, Generaux C, 
Bridges A, Hall JE and Boykin DW (2006) Synthesis, DNA affinity, and 
antiprotozoal activity of linear dications: Terphenyl diamidines and 
analogues. J Med Chem 49:5324-5332. 
95 
Ismail MA, Brun R, Easterbrook JD, Tanious FA, Wilson WD and Boykin DW 
(2003) Synthesis and antiprotozoal activity of aza-analogues of 
furamidine. J Med Chem 46:4761-4769. 
Kennedy PG (2008) The continuing problem of human African trypanosomiasis 
(sleeping sickness). Ann Neurol 64:116-126. 
Lutje V, Seixas J and Kennedy A (2010) Chemotherapy for second-stage Human 
African trypanosomiasis. Cochrane Database Syst Rev 8:CD006201. 
Mathis AM, Bridges AS, Ismail MA, Kumar A, Francesconi I, Anbazhagan M, Hu 
Q, Tanious FA, Wenzler T, Saulter J, Wilson WD, Brun R, Boykin DW, 
Tidwell RR and Hall JE (2007) Diphenyl furans and aza analogs: effects of 
structural modification on in vitro activity, DNA binding, and accumulation 
and distribution in trypanosomes. Antimicrob Agents Chemother 51:2801-
2810. 
Mathis AM, Holman JL, Sturk LM, Ismail MA, Boykin DW, Tidwell RR and Hall JE 
(2006) Accumulation and intracellular distribution of antitrypanosomal 
diamidine compounds DB75 and DB820 in African trypanosomes. 
Antimicrob Agents Chemother 50:2185-2191. 
Midgley I, Fitzpatrick K, Taylor LM, Houchen TL, Henderson SJ, Wright SJ, 
Cybulski ZR, John BA, McBurney A, Boykin DW and Trendler KL (2007) 
Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N-
methoxyamidino)phenyl]furan monomaleate) in rat and monkey and its 
conversion to the antiprotozoal/antifungal drug DB75 (2,5-bis(4-
guanylphenyl)furan dihydrochloride). Drug Metab Dispos 35:955-967. 
Ming X, Ju W, Wu H, Tidwell RR, Hall JE and Thakker DR (2009) Transport of 
dicationic drugs pentamidine and furamidine by human organic cation 
transporters. Drug Metab Dispos 37:424-430. 
Ohta KY, Inoue K, Hayashi Y and Yuasa H (2006) Molecular identification and 
functional characterization of rat multidrug and toxin extrusion type 
transporter 1 as an organic cation/H+ antiporter in the kidney. Drug Metab 
Dispos 34:1868-1874. 
Ohta KY, Inoue K, Yasujima T, Ishimaru M and Yuasa H (2009) Functional 
characteristics of two human MATE transporters: kinetics of cimetidine 
transport and profiles of inhibition by various compounds. J Pharm Pharm 
Sci 12:388-396. 
Olson CA (2010) Pafuramidine Pathology Reports, Personal communication, 
Immtech Pharmaceuticals, Inc. 
96 
Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H and Moriyama Y 
(2005) A human transporter protein that mediates the final excretion step 
for toxic organic cations. Proc Natl Acad Sci U S A 102:17923-17928. 
Paine MF, Wang MZ, Generaux CN, Boykin DW, Wilson WD, De Koning HP, 
Olson CA, Pohlig G, Burri C, Brun R, Murilla GA, Thuita JK, Barrett MP 
and Tidwell RR (2010) Diamidines for human African trypanosomiasis. 
Curr Opin Investig Drugs 11:876-883. 
Quiros Y, Vicente-Vicente L, Morales AI, Lopez-Novoa JM and Lopez-Hernandez 
FJ (2010) An integrative overview on the mechanisms underlying the renal 
tubular cytotoxicity of gentamicin. Toxicol Sci. 
Reisner HM, Gray DR, Jones SK, Rose BG and Tidwell RR (2000) 
Immunoassays for pentamidine and related compounds: development of a 
facile inhibitory ELISA suitable for clinical use. J Clin Lab Anal 14:73-82. 
Saulter JY, Kurian JR, Trepanier LA, Tidwell RR, Bridges AS, Boykin DW, 
Stephens CE, Anbazhagan M and Hall JE (2005) Unusual dehydroxylation 
of antimicrobial amidoxime prodrugs by cytochrome b5 and NADH 
cytochrome b5 reductase. Drug Metab Dispos 33:1886-1893. 
Tanihara Y, Masuda S, Katsura T and Inui K (2009) Protective effect of 
concomitant administration of imatinib on cisplatin-induced nephrotoxicity 
focusing on renal organic cation transporter OCT2. Biochem Pharmacol 
78:1263-1271. 
Wang MZ, Saulter JY, Usuki E, Cheung YL, Hall M, Bridges AS, Loewen G, 
Parkinson OT, Stephens CE, Allen JL, Zeldin DC, Boykin DW, Tidwell RR, 
Parkinson A, Paine MF and Hall JE (2006) CYP4F enzymes are the major 
enzymes in human liver microsomes that catalyze the O-demethylation of 
the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-
methylamidoxime]. Drug Metab Dispos 34:1985-1994. 
Ward CP, Burgess KE, Burchmore RJ, Barrett MP and de Koning HP (2009) A 
fluorescence-based assay for the uptake of CPD0801 (DB829) by African 
trypanosomes. Mol Biochem Parasitol 174:145-149. 
Wenzler T, Boykin DW, Ismail MA, Hall JE, Tidwell RR and Brun R (2009) New 
treatment option for second stage African sleeping sickness: In vitro and in 
vivo efficacy of aza analogs of DB289. Antimicrob Agents Chemother. 
Yan GZ, Brouwer KL, Pollack GM, Wang MZ, Tidwell RR, Hall JE and Paine MF 
(2011) Mechanisms Underlying Differences in Systemic Exposure of 
Structurally Similar Active Metabolites: Comparison of Two Preclinical 
Hepatic Models. J Pharmacol Exp Ther electronic publication ahead of 
print. 
97 
Yasujima T, Ohta KY, Inoue K, Ishimaru M and Yuasa H (2010) Evaluation of 
4',6-diamidino-2-phenylindole as a fluorescent probe substrate for rapid 
assays of the functionality of human multidrug and toxin extrusion 
proteins. Drug Metab Dispos 38:715-721. 
Yun O, Priotto G, Tong J, Flevaud L and Chappuis F (2010) NECT is next: 
implementing the new drug combination therapy for Trypanosoma brucei 
gambiense sleeping sickness. PLoS Negl Trop Dis 4:e720. 
Zhou L, Thakker DR, Voyksner RD, Anbazhagan M, Boykin DW, Hall JE and 
Tidwell RR (2004) Metabolites of an orally active antimicrobial prodrug, 
2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime, identified by liquid 
chromatography/tandem mass spectrometry. J Mass Spectrom 39:351-
360. 
 
 
 
Chapter 4:  
Why CPD-0801 Development Should Continue  
 
Human African trypanosomiasis (HAT) is a fatal disease with no highly 
effective, non-toxic, easy to administer drug treatment.  Development of 
pafuramidine, a prodrug of furamidine, for first stage HAT was terminated due to 
delayed nephrotoxicity observed in an expanded phase I safety trial.  This failure 
was a major setback in efforts to develop new drugs to treat and control HAT.  
CPD-0801, an analog of furamidine, is currently in preclinical development for 
second stage HAT.  Unlike pafuramidine and furamidine, CPD-0801 is curative in 
second stage murine and simian models of HAT; it is the only new compound 
efficacious in both models.  CPD-0801 could be developed as a new drug for 
HAT, to be given intramuscularly in patients, like pentamidine. 
As discussed previously in this dissertation, mechanisms causing the 
delayed nephrotoxicity seen in the expanded phase I safety study of 
pafuramidine are not clear.  One possibility is that the longer dosing regimen 
used in the clinical study may have led to high accumulation of pafuramidine in 
the kidney, and thus delayed nephrotoxicity.  Pafuramidine development was 
discontinued.  Drug accumulation in various cell types can lead to long term 
cellular exposure to high levels of the compound.  Indeed, accumulation of the 
drug in a critical compartment creates the potential for toxicity.  Radiolabeled 
pafuramidine  was detected in tissues by whole body autoradiography (Figure 5) 
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(Midgley et al., 2007).  Since tissue concentrations of pafuramidine and its 
metabolites were not accurately assayed over time as with plasma 
concentrations, In addition, no evidence for kidney toxicity was observed in 
extensive preclinical toxicity studies done in rats and cynomolgus monkeys.   
CPD-0801 has the potential to successfully treat second stage HAT.  
However, because it is structurally similar to furamidine, the active metabolite of 
pafuramidine, it is critical to demonstrate that CPD-0801 will not cause 
nephrotoxicity like pafuramidine.  Without this assurance, continued development 
of CPD-0801 for second stage HAT is not possible, leaving patients with no 
alternatives to the current drugs available.    
Rat Kidney Exposure to CPD-0801 is Less than Furamidine 
Kidney sequestration of orally administered pafuramidine, a bis-O-
methylamidoxime prodrug of the active diamidine furamidine, could not be 
directly compared to sequestration of the parenterally administered new 
diamidine candidate, CPD-0801.  Only furamidine, however, of the known 
metabolites, was detected in rat kidney eight days after oral administration with 
pafuramidine.  Since radiolabeled compound was not available to perform mass 
balance studies for the current studies, it is possible that an unknown metabolite, 
or a metabolite that was covalently bound to protein or other macromolecule, 
might have been formed that was responsible for pafuramidine‟s nephrotoxicity.  
A metabolite covalently bound to protein would precipitate during the sample 
preparation for LC/MS/MS and would not be detected.  However, mass balance 
studies were performed using livers, but not kidneys, from rats dosed with 
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pafuramidine; all radioactivity was recovered from liver as furamidine three days 
after administration (Midgley et al., 2007).  This observation, combined with the 
large amount of furamidine still contained in rat kidneys eight days after 
administration of pafuramidine in the current studies, suggests that furamidine 
was the toxic agent.  Therefore, CPD-0801 was compared to furamidine.   
After identifying the probable toxic agent as furamidine, the next step was 
to directly compare kidney exposure of furamidine and CPD-0801.  The 
comparison is particularly important because the plasma exposure (AUC) of 
CPD-0801 was approximately double that of furamidine.  If plasma exposure 
alone was used to monitor CPD-0801 toxicity, it would be reasonable to 
hypothesize that CPD-0801 might be more toxic than its close analog, 
furamidine.  However, kidney exposure of CPD-0801 was 14 times less than 
furamidine.  If duration and extent of kidney exposure are important determinants 
of nephrotoxicity for both diamidines, then these data would suggest that CPD-
0801 may be less nephrotoxic than furamidine and consequently, improves the 
prospects of continued development of CPD-0801.   
Diamidine Accumulates Primarily in Proximal Tubule Cells 
As discussed in Chapter 1, organic cations are transported across renal 
proximal tubule cells.  Many cationic exogenous compounds and drugs are 
cleared through the kidney by uptake from blood into renal proximal tubule cells 
(the basolateral side) by OCT1 and OCT2 (Lee and Kim, 2004; Wright, 2005).  
Efflux from proximal tubule cells into the urinary space  at the apical side occurs 
through multiple organic cation transporters (Lee and Kim, 2004; Wright and 
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Dantzler, 2004; Greenberg, 2009), including MATE1, which has been shown to 
transport DAPI, a diamidine (Yasujima et al., 2010).  CPD-0801 and furamidine 
must utilize transport proteins because they are positively charged at 
physiological pH and cannot cross cell membranes by passive diffusion.  Urinary 
excretion of CPD-0801 was 3.5 times greater than furamidine, suggesting that 
both uptake and efflux organic cation transporters may be involved.   
Both CPD-0801 and furamidine accumulated in the outer stripe of the 
outer medulla (referred to as the outer stripe).  At earlier time points, notably six 
hours after dosing, both diamidines were detected in the cortex, as well as the 
outer stripe, specifically in the proximal tubules.  This suggested the involvement 
of organic cation transporters in uptake of CPD-0801 and furamidine into renal 
cells.  To visualize CPD-0801 and furamidine with confidence, the inherent 
fluorescence of the compounds was used alongside immunohistochemistry.  
Although both methods render the diamidines visible to the microscope, they do 
so through different detection methods with method-dependent pitfalls.   
CPD-0801 and furamidine fluorescence can be viewed using widefield and 
laser scanning confocal microscopy.  Visualization of diamidines by inherent 
fluorescence does not require treatment of the tissue sections.  However,  
fluorescence of these compounds is known to be quenched upon their binding to 
DNA (Mathis et al., 2007).  In addition, CPD-0801 does not appear to fluoresce 
as intensely as furamidine in tissues, consistent with previous observations 
(Mathis et al., 2007) and may thus be more difficult to detect at lower 
concentrations despite similar fluorescence intensities in solution.  Finally, 
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visualization by fluorescence when dosing CPD-0868 or pafuramidine is 
problematic because the prodrugs and all the metabolites are excited at the 
same wavelength and have almost the same emission spectra.  To overcome 
these difficulties, an antibody approach was used.   
A monoclonal antibody was developed against mono-aminopentamidine 
for use in the study of pentamidine.  The advantage of developing this antibody is 
that it enables the use of traditional protein-based techniques, such as enzyme-
linked immunosorbant assay (ELISA) and immunohistochemistry (IHC), with 
small-molecules.  The disadvantage of using an antibody is that it is usually 
highly specific for the antigen of choice.  Consequently, it was first necessary to 
demonstrate that the antibody made for pentamidine would specifically recognize 
the newer diamidines (CPD-0801 or furamidine) before visualization by IHC.   
Using an inhibitory ELISA (IELISA), both CPD-0801 and furamidine were 
recognized by the anti-pentamidine monoclonal antibody.  To insure that the 
recognition would be sufficiently specific for use in IHC, the antibody was also 
tested on the prodrugs, CPD-0868 and pafuramidine, and their intermediate 
metabolites.  This group of molecules was chosen for testing to insure that the 
antibody would be able to differentiate the prodrugs from the active diamidines 
since fluorescence is unable to do so.  Additionally, the prodrugs and metabolites 
are more similar to the diamidines than endogenous molecules in tissue, insuring 
high specificity.  The data discussed in Chapter 2 showed that the monoclonal 
antibody (Mab 1.85.72) specifically recognizes the amidine moiety.  The central 
portion of the molecule does play some role since the binding affinity to 
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pentamidine is higher than furamidine or CPD-0801, but further structure-binding 
affinity studies are needed to fully understand epitope recognition.   
Thus, it was ascertained that Mab 1.85.72 had sufficiently high binding 
affinity to CPD-0801 and furamidine for IHC to be effective.  IHC studies 
determined that immunostaining of rat kidneys treated with CPD-0801 and 
furamidine correlated well with the observed inherent fluorescence.  The outer 
stripe was distinctly stained by IHC, and the staining was specific to the proximal 
tubules.  Given the correlation between two very different detection methods, 
inherent fluorescence and immunostaining, there is a high degree of confidence 
that furamidine and CPD-0801 were accurately visually localized.  Additionally, 
this work has provided a new method for visualizing small molecules in the form 
of immunostaining, which was previously only used for macromolecule detection.   
Unfortunately, the same comparative technique could not be used 
between the inherent fluorescence and immunofluorescence (IF).  As described 
in Chapter 3, Mab 1.85.72 did not have sufficiently high affinity to use for sub-
cellular localization.  The data indicated that the IF staining corresponded to the 
same cells that exhibited inherent fluorescence of furamidine.  However, inherent 
fluorescence did not overlap spatially with the antibody signal, which may 
indicate that the antibody does not bind to all of the compound present in the 
tissue.  Because it could not be demonstrated that the antibody recognized all 
the diamidine present in each cell, sub-cellular localization was done with 
inherent fluorescence alone.   
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Throughout the study of pafuramidine and furamidine, a pattern has 
emerged in kidney pathology and drug distribution.  Previous studies showed a 
distinct band of radioactivity in the kidney of rats dosed with pafuramidine in 
whole body autoradiographic images.  In human trials of pafuramidine, one of the 
patient biopsy samples was described as having “collections of epithelioid 
histeocytes forming poorly formed granulomas surrounded by inflammatory 
cells,” specifically at the “corticomedullary junction” (Olson, 2010).  This 
increased inflammation was noted in the outer stripe region in a human subject 
experiencing pafuramidine-induced delayed nephrotoxicity.  Additionally, work by 
Dr. Kristina DeSmet of The Hamner Institute has shown that rats experiencing 
acute mild pafuramidine-induced nephrotoxicity demonstrate more severe tubule 
damage in the outer stripe of the kidney (DeSmet, 2010).  This work has shown 
that furamidine, dosed alone or metabolized from pafuramidine, accumulates 
specifically in the outer stripe of rat kidney for long periods of time.   
Transport Proteins May Be Responsible for Cell Type Specificity 
Renal Excretion Leads to a Transport Hypothesis 
The data demonstrated that CPD-0801 accumulates less in the kidney 
than furamidine, but can only suggest possible reasons for this difference.  From 
the data, furamidine concentration in the kidney declined in a mono-exponential 
fashion, whereas CPD-0801 decline was bi-exponential.  Initially, it was thought 
this difference in curve shape could possibly be caused by improved efflux 
transport of CPD-0801, due to the substitution of the benzene rings by pyridine, 
resulting in superior transport protein recognition of CPD-0801 relative to 
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furamidine.  Additionally, the significantly lower accumulation of CPD-0801 in the 
kidney compared to furamidine might also be explained by variations in efflux 
transport.  Imaging data showed that both CPD-0801 and furamidine were found 
in proximal tubule cells, which contain transporters that could facilitate diamidine 
transport (Baldwin et al., 2004; Gray et al., 2004; Lee and Kim, 2004; Wright and 
Dantzler, 2004; Wright, 2005; Greenberg, 2009; Ming et al., 2009).  However, 
while the fluorescence and IHC data may support a transporter based 
hypothesis, the data do not specify whether excretion is basolateral (into the 
plasma) or apical (into the urine) (Figure 21).   
Plasma levels of furamidine and CPD-0801 after 24 h were below the limit 
of detection by LC/MS/MS methods.  As expected, CPD-0801 was excreted into 
the urine.  The amount of CPD-0801 excreted into the urine after 24 h correlates 
with the rapid initial decrease in the amount of CPD-0801 in the kidney.  
Furamidine also accumulated in the urine, but in very low levels, consistent with 
the data when dosing pafuramidine orally to rats (Midgley et al., 2007).  
Differences in CPD-0801 and furamidine urinary excretion could indicate 
differences in efflux transport on the apical side, but even with the imaging data, 
alternative hypotheses are not eliminated.   
There are multiple steps involved in the processing of small molecules by 
the kidney.  The first step is filtration by the glomerulus.  Both furamidine and 
CPD-0801 are likely filtered by the glomerulus because they are small molecules 
(< 500 daltons) with substantial unbound fractions in plasma (> 0.1).  However, it 
is unlikely that differences in glomerular filtration impacted differences in  
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Figure 21 Renal proximal tubule transport of diamidines.  Solid arrows 
represent known transporters of furamidine and CPD-0801; dashed arrows 
represent possible transporters for which diamidines may be substrates.  
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accumulation and excretion because the renal clearances were at least a tenth of 
the glomerular filtration rate before binding to plasma proteins was taken into 
account, and at least three times lower after correction for plasma binding.  Once 
the diamidines have entered the cells, the accumulation differences between 
CPD-0801 and furamidine might be explained by covalent binding to a specific 
moiety (such as a protein or other macromolecule) within the cell.  Studies 
demonstrating accumulation differences were carried out by LC/MS/MS.  
LC/MS/MS could not detect a compound covalently bound to a macromolecule in 
the cell because all proteins are precipitated in the sample preparation process.  
Therefore, covalent binding is unlikely to account for the accumulation 
differences observed by LC/MS/MS.   
Reabsorptive and secretory transport are important processes in the 
kidney and they might be responsible the differences between CPD-0801 and 
furamidine.  Reabsorption involves transport proteins that take up small 
molecules from the filtrate back into the kidney cells.  Because both diamidines 
could also enter the cells from the plasma, reabsorption is less likely to be a 
major factor in the kidney exposure of the two diamidines.  Reabsorption may 
explain the higher Cmax (14 μM) of furamidine compared to CPD-0801 (5.4 μM), 
but not differences in excretion.  Secretion is transport in the reverse direction, 
from the cells into the filtrate.  These two factors cannot be separated without 
studying specific transporters involved in each mechanism.  This line of thought 
returns to the hypothesis that efflux transporters, responsible for secretion, are a 
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key factor in the differences in CPD-0801 and furamidine accumulation and 
elimination.   
CPD-0801 and Furamidine Are Substrates for an Apical Efflux Transporter 
Based on the hypothesis that an increased affinity for efflux transporters is 
responsible for increased CPD-0801 elimination compared to furamidine, apical 
(efflux) membrane transporters were investigated.  Those that best fit the criteria 
were selected for further investigation.  The selection criteria were based largely 
on structural similarities of preferred substrates.  MATE1 was selected as the 
primary apical transporter of interest because it transports many organic cations 
from proximal tubule cells in the kidney (Ohta et al., 2006; Nishihara et al., 2007; 
Ohta et al., 2009; Nakamura et al., 2010); DAPI, a diamidine, is a known 
substrate for MATE1 (Yasujima et al., 2010).  Both CPD-0801 and furamidine 
were substrates for MATE1.  The differences in diamidine uptake upon partial 
inhibition of MATE1 with MPP (1-methyl-4-phenylpyridinium) may suggest that 
furamidine and CPD-0801 have different affinities for MATE1.  However, these 
studies are insufficient for calculations of transport efficiency.  The partial 
inhibition of MATE1 by MPP may also reflect an MPP-independent diamidine 
sequestration process in CHO cells.  Since the differences in MATE1 transport of 
CPD-0801 and furamidine seem to be minimal compared to the differences in 
kidney accumulation, it is unlikely that variations in efflux transport were solely 
responsible for the variations in accumulation.   
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Diamidine Basolateral Transport is OCT1/2 Independent 
Kidney slices were utilized as a method of assessing basolateral transport 
of these diamidines.  As previously discussed, there are two key organic cation 
transporters on the basolateral side of proximal tubule cells, OCT1 and OCT2.  
Both furamidine and CPD-0801 were found to be substrates for OCT1 (Figure 
8), and furamidine is a known substrate for OCT2 (Ming et al., 2009).  Based on 
this previous work, kidney slices were used to analyze all basolateral 
transporters simultaneously.  Because kidney slices lack a lumen (Crljen et al., 
2005), it was expected that furamidine would be taken up into proximal tubule 
cells in higher concentrations than CPD-0801 since the maximum concentration 
(Cmax) of furamidine in rat kidney was higher than CPD-0801 (Table 9).   
Kidney slices were treated with CPD-0801 or furamidine with and without 
MPP.  MPP is known to at least partially inhibit OCT1/2 at the concentration used 
(Lee et al., 2009).  Additionally, it was expected that MPP would at least partially 
inhibit all organic cation uptake transporters, as it is known to be a promiscuous 
inhibitor (Lee et al., 2009; Ohta et al., 2009).  The results of the kidney slice study 
were in direct contrast to expectations.  Less furamidine than CPD-0801 was 
taken up into the kidney slices.  The presence of MPP, expected to block 
transport, increased furamidine uptake and had no effect on CPD-0801 uptake.  
There are two possible explanations for these unexpected results: (1) apical 
efflux is occurring in the kidney slices, or (2) another basolateral efflux 
transporter is involved.    
It is unlikely that apical efflux transport is occurring in kidney slices.  
Previous studies have consistently shown that kidney slices do not have a 
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functional lumen (Chambers and Kempton, 1933; Berndt, 1976; Crljen et al., 
2005).  Without a functional lumen, apical transport cannot occur.  Additionally, if 
furamidine and CPD-0801 were an exception to this rule, fluorescence would 
have been observed in the luminal spaces, which it was not.  If apical efflux 
occurred in the kidney slices, it would be expected that treatment with MPP 
would block MATE1, thus resulting in an increased level of CPD-0801 in the 
kidney.  Since no change in CPD-0801 levels was detected, apical efflux is an 
unlikely source for the increase in furamidine concentrations upon treatment with 
MPP.   
The increase in furamidine uptake into kidney slices upon treatment with 
MPP was unexpected given that furamidine is a known OCT1/2 substrate.  The 
concentration of furamidine in the control was more than 10-fold lower than the 
initial concentration of furamidine given, suggesting that furamidine basolateral 
efflux transport may be important.  However, CPD-0801 is not a substrate for this 
transporter, which rules out the bi-directionality of OCTs since CPD-0801 is a 
known OCT1 substrate and MPP is a potent OCT inhibitor.  There are very few 
basolateral efflux transport proteins for which diamidines may be substrates.  
This is because basolateral efflux is designed to return essential molecules to the 
circulation and is therefore more specific in substrate selection than transport 
proteins involved in elimination of exogenous compounds.  Equilibrative 
nucleoside transporter 1 (ENT1) moves purines and pyrimidines between 
proximal tubule cells and blood (Baldwin et al., 2004).  It is possible that due to 
the ring structure of furamidine, it could be an ENT1 substrate.  With two pyridine 
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rings instead of phenyl rings, CPD-0801 is more likely to be an ENT1 substrate 
than furamidine.  Additionally, it is unlikely that MPP would inhibit ENT1 based on 
its structure, although no data on this could be found.  Based on an 
understanding of ENT1 substrates, it seems unlikely that the efflux of furamidine 
from kidney tissue slices was facilitated by ENT1 transport.  However, ENT1 
transport may explain why CPD-0801 uptake was unaffected by MPP.  This 
hypothesis could be tested in ENT1 transfected cells treated with CPD-0801 with 
MPP or a known ENT1 inhibitor, such as 6-S-[(4-nitrophenyl)methyl]-6-
thioinosine (Takano et al., 2010).  The basolateral transport of diamidines in rat 
kidney is not currently well understood, but OCT1 and OCT2 do not seem to play 
a major role.   
Tissue Binding May Correlate with Differences in Renal 
Accumulation 
Based on work by Drs. Grace Yan and Claudia Generaux (Generaux, 
2010; Yan, 2010; Yan et al., 2011), binding was considered as an alternative 
hypothesis.  For a compound to be available for efflux transport, it cannot be 
tightly bound to cellular elements.  Consequently, if a compound has a very low 
unbound fraction, it may not be readily available for transport.  It had been 
previously demonstrated using compartmental modeling that after pafuramidine 
administration, furamidine elimination from the liver was most likely binding-
dependent (Yan et al., 2011).  Therefore, it was thought that the differences in 
furamidine and CPD-0801 elimination from the kidney may also be binding-
dependent.  CPD-0801 has a lower binding affinity to genomic and kinetoplast 
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DNA than furamidine (Kd of approximately 1 μM and 0.1 μM for CPD-0801 and 
furamidine, respectively) (Mathis et al., 2007).  The differences in DNA binding 
are mirrored in the differences between plasma and kidney tissue binding.  The 
unbound fraction of CPD-0801 is four times higher than furamidine in plasma and 
12 times higher than furamidine in kidney.  Although more furamidine was 
detected in the kidney compared to CPD-0801, five times the amount of CPD-
0801 is estimated to be unbound in renal proximal tubule cells.  Therefore, it 
appears that tissue binding, not transport, may explain the difference in 
accumulation of CPD-0801 and furamidine.   
Differences in tissue binding seem to explain differences in CPD-0801 and 
furamidine accumulation in the kidney, but binding does not seem to be involved 
in the specific localization of furamidine and CPD-0801 to the proximal tubule 
cells in the outer stripe of the outer medulla.  For binding to be involved in cell 
type specificity, the diamidines would have to bind to some specific cellular 
structure or molecule within proximal tubule cells.  However, based on tissue 
binding, plasma binding and buffer controls, furamidine has a consistently lower 
unbound fraction than CPD-0801, suggesting that the binding may be non-
specific and therefore unrelated to cell specificity.   
Clinical Implications 
In addition to the basic science implications of this work, these studies 
have potential translational impact for both the future of HAT treatment and drug 
development in general.   
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The concentration-time data from rat kidney generated for this work were 
also used by Dr. Grace Yan to create a semi-physiologically-based 
pharmacokinetic model (PBPK) of pafuramidine (Yan, 2010).  Using the semi-
PBPK model, Dr. Yan hypothesized that, when taking into account kidney 
accumulation of furamidine over time, alternative dosing regimens might be 
developed that could prevent increasing concentrations of a potentially toxic 
moiety in the kidney while maintaining sufficiently effective levels of furamidine in 
the plasma.  This type of modeling could potentially be used to develop 
alternative dosing regimens for CPD-0801 based on tissue accumulation.   
In addition to providing clues about toxicity in a compound class, this 
project also addresses possible methods for improving the drug development 
process.  Both compound selection and subject safety during preclinical and 
clinical trials could be positively impacted by this work.  By focusing on 
compound properties such as binding and urinary excretion, it may be possible to 
predict potential nephrotoxicity before a drug candidate is given to a patient.  
During the “hit to lead” process in drug development a compound that 
demonstrates efficacy in an in vitro screen enters an arduous process where 
chemists produce a variety of structural modifications to generate superior lead 
compounds.  A successful lead compound usually demonstrates superior 
efficacy in the in vitro screen and favorable physiochemical properties.  What is 
often not taken into account at that time is the potential for toxicity.  This issue is 
dealt with in animal and human studies that occur after a lead is selected.  A 
significant advantage of the diamidine class revealed by this work is that toxicity 
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may be directly related to tissue accumulation (a theory that could be further 
validated with a rodent model of pafuramidine-induced nephrotoxicity).  Tissue 
accumulation is directly related to tissue binding, which could be measured in a 
semi-high throughput in vitro screen.  Therefore, all future diamidines could be 
screened simultaneously for efficacy and toxicity during hit-to-lead selection, 
resulting in potentially safer candidates moved into the lead optimization process 
and future development.  Further studies are needed to demonstrate that other 
known toxic diamidines, such as pentamidine, follow this pattern to substantiate 
the connection between binding, toxicity and accumulation.  However, it should 
be remembered that tissue binding and accumulation may be only one 
mechanism for potential diamidine toxicity.   
Another practical application of this research is the antibody developed for 
use with the imaging techniques.  The antibody discussed could also be used 
with the IELISA as an added safety measure in human clinical trials.  The IELISA 
could be modified into an inexpensive kit for CPD-0801 detection in urine.  
Diamidine urine output appear to be inversely related to kidney exposure in rats, 
a pattern that could likely be extrapolated to humans.  Substantially lower CPD-
0801 urine levels in one subject as compared to others in a group could be 
indicative of potentially high kidney levels that could lead to toxicity.  Early clinical 
trial data with CPD-0801 could be used in conjunction with rodent accumulation 
data to predict a threshold for diamidine urine output.  Below this threshold, CPD-
0801 output into the urine would be low, indicating high kidney accumulation and 
increased risk for nephrotoxicity.  Through careful selection of a primary antibody 
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concentration, an IELISA could be designed to change color only above the 
selected threshold.  A kit could be developed for use in the field during efficacy 
studies in sub-Saharan Africa.  Patients could have their urine tested at the same 
time as receiving CPD-0801 for treatment of HAT.  If the sample fails to turn 
color, then it would indicate that the patient has unacceptably low CPD-0801 
urinary output and is possibly at risk for delayed nephrotoxicity.  Since the IELISA 
is inexpensive, rapid and easy to transport, results could be available within four 
hours and the patient would stop receiving treatment the same day.  This could 
provide patients with an additional level of safety in future CPD-0801 clinical 
trials.  However, used in this manner, the IELISA would result in diamidine 
concentration per unit of urine, which could be misleading without knowing total 
urinary output in a 24-hour period.  Assessing urinary output in the rural locations 
where HAT occurs would be challenging so use of the IELISA may only be 
feasible for patients with second stage disease, who are usually hospitalized, or 
in a select portion of subjects.   
Future Directions 
Epitope Mapping with Small Molecules 
Epitope mapping is the process by which the shape of the antigen 
recognition site is determined for a given antibody.  The majority of antibodies 
are created against a protein antigen.  Traditionally, the gold standard technique 
for epitope mapping is x-ray co-crystallography, because the antigen and 
antibody are visualized while bound.  In addition to x-ray co-crystallography, 
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peptide scanning and mutagenesis can be used to map an antigen binding 
pocket (Mahler and Fritzler, 2010).   
The data in Chapter 2 indicate that an amidine moiety is required for Mab 
1.85.72 binding.  However, the importance of the central portion of the molecule 
to antibody binding is not well understood.  Although x-ray co-crystallography is a 
technique that could potentially be used with a small molecule, it requires large 
amounts of antigen and antibody (Mahler and Fritzler, 2010).  However, peptide 
scanning and mutagenesis are not possible with a small molecule antigen.   
To do epitope mapping with Mab 1.85.72, a modification of the peptide 
scanning method could be used.  A vast library of amidine containing molecules 
is available at University of North Carolina at Chapel Hill and Georgia State 
University.  Using this library, molecules could be tested for antibody binding 
using the IELISA described in Chapter 2.  Correlations between antibody binding 
and structure (one amidine versus two, aromatic central portion versus 
hydrocarbon chain, etc.) could effectively „map‟ the binding site requirements for 
Mab 1.85.72 as would be done with small peptides for more traditional 
antibodies.   
Sub-cellular Localization of Diamidines 
The fluorescence of CPD-0801 and furamidine showed that the 
compounds accumulate in specific unidentified structures in the cytoplasm.  The 
sub-cellular localization of CPD-0801 and furamidine raised new questions into 
the behavior of diamidines in rat kidney.  The most immediate question was „To 
what structures in the kidney are the compounds localized?‟  Once these 
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structures are identified, they could have implications for the mechanism of 
pafuramidine-induced delayed nephrotoxicity.  For example, if the cytoplasmic 
structures that co-localize with furamidine fluorescence are found to be 
mitochondria, the delayed nephrotoxicity in humans may be metabolic in nature.  
Previous studies have also shown that organic cations can be sequestered in 
acidic compartments such as endosomes, lysosomes or golgi vesicles (Pritchard 
and Miller, 1996).  Intracellular sequestration may allow a much higher 
intracellular concentration of organic cations than would be expected based on 
the electrochemical potential across the cell membrane (Pritchard and Miller, 
1996).   
Using the data discussed in Chapter 3, a three-dimensional image of the 
renal cortex six hours after dosing furamidine was created (Figure 22).  Based 
on the inherent fluorescence, surfaces were created to visualize the sub-cellular 
structures.  These structures could represent mitochondria, endosomes, 
lysosomes, golgi vesicles, acidic compartments, or a variety of other structures.  
Therefore, although this is a useful way to image inherent fluorescence, it does 
not elucidate specific structures.   
Immunofluorescent (IF) staining or dyes could be used to label each 
organelle in an attempt to co-localize the fluorescence of furamidine or CPD-
0801 to a known sub-cellular compartment.  The difficulties with this technique 
are in finding specific antibodies and/or dyes for each organelle and correctly 
deducing the sub-cellular structure that contains the diamidine.  A prime example 
of this difficulty is specifically staining mitochondria, a significant structure of  
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Figure 22 Surface analysis of furamidine inherent fluorescence.  A rat was 
administered furamidine by intravenous infusion (10 μmol/kg over 30 s) and 
sacrificed six hours post-administration.  Paraffin embedded slides were treated 
with a staining protocol for maximal visualization of the inherent fluorescence of 
diamidine compound (green).  Laser scanning confocal (excitation 405 nm) was 
used to obtain a magnified image of the cortex.  Glomeruli (G) and select 
proximal tubules (P) are shown.  Surfaces were artificially created based on 
intensity using Imaris software (Bitplane Inc., Zurich, Switzerland).  The surfaces 
were colored based on intensity as indicated by the legend.  The white bar 
represents 5 μm.   
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interest.  The majority of mitochondrial stains and dyes are based on the 
functionality of the mitochondria (for example: rhodamine 123 and 
tetramethylrosamine) (Johnson and Spence, 2011).  Dyes that are maintained in 
the cell after fixation, such as MitoTracker Probes (Johnson and Spence, 2011), 
still require mitochondrial function to localize properly.  Alternatives to dyes and 
stains include antibodies to mitochondria-specific proteins, or avidin binding to 
endogenous biotin carboxylase enzymes (Kirkeby et al., 1993).  None of these 
options are ideal.  A dye or stain would be preferred as they are less likely to 
interfere with the inherent fluorescence of the diamidines than an antibody.  
However, for fixed tissues immunostaining is often the best option.   
The difficulties intrinsic to staining, dying or tagging each sub-cellular 
structure of interest could be circumvented by use of transmission electron 
microscopy (TEM).  The advantage of TEM is that it reveals the structure of the 
cell, potentially identifying a previously unexpected organelle.  However, 
immunolabeled TEM requires a monoclonal antibody with both high affinity and 
specificity, similar to IF.  Because Mab 1.85.72 is not high enough affinity for IF, 
higher affinity monoclonal antibodies would need to be developed against both 
furamidine and CPD-0801 to achieve the affinity necessary for immunolabeled 
TEM.  It is possible that Mab 1.85.72 could be used for TEM or IF, but extensive 
modification to the staining protocol would be needed, with a focus on antigen 
retrieval and membrane permeability.   
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Diamidine Binding Specific to Sub-cellular Structures 
To test the hypothesis that CPD-0801 and furamidine binding is non-
specific, kidney tissue could be fractionated using density gradient ultra-
centrifugation and diamidine binding to each fraction assessed.  However, if the 
non-specific binding hypothesis is correct, it would be expected that furamidine 
would have a consistently smaller unbound fraction in all binding studies, 
including the fractions that contain DNA (both diamidines are known to bind to 
DNA with different affinities).  This study is similar to one done with radioactive 
pafuramidine (Midgley et al., 2007).  However, the previous work used organs 
from rats treated with compound in vivo and then fractionated.  The length of time 
needed to fractionate tissue could allow the compounds to redistribute, muddling 
the results.  By fractionating the tissue and then adding compound, reliable 
unbound fractions could be calculated.  The anticipated results of this experiment 
would lend credence to the hypothesis that the smaller unbound fraction of 
furamidine compared to CPD-0801 in kidney tissue is due to non-specific binding 
and therefore unrelated to localization.   
Additional Transporter Studies 
The kidney slice experiment discussed in Chapter 3 requires further 
studies to fully interpret the results.  First, to insure that no apical transport 
occurred in the kidney slices, the experiment should be repeated with 
pyrimethamine, a specific MATE1 inhibitor (Ito et al., 2010).  It is expected that 
the addition of pyrimethamine would have no impact on the results of the 
experiment because kidney slices should have no luminal transport.   
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The kidney slice study suggested that CPD-0801 basolateral uptake is 
OCT1/2 independent.  This could be demonstrated by dosing OCT1/2 knockout 
mice with CPD-0801 and measuring diamidine levels in the kidney.  If CPD-0801 
uptake is OCT1/2 independent, then the compound should still accumulate in the 
kidney.  ENT1 is considered a viable alternative for CPD-0801 uptake from the 
plasma, and CNT1 a possibility for reabsorption from the filtrate.  CPD-0801 
uptake into ENT1 and CNT1 transfected cells (as was done with MATE1) should 
be measured to assess the ability for CPD-0801 to utilize these transport 
proteins.   
Furamidine uptake, or lack thereof, into the kidney slices seemed to 
suggest the involvement of a basolateral efflux transport protein.  Although 
furamidine seems to be an unlikely candidate for ENT1, furamidine uptake into 
ENT1 transfected cells should still be assessed.  In addition to basolateral 
transport, it is possible that MPP disrupts intracellular binding or sequestration 
through an unknown mechanism that does not seem to occur in CHO cells.  To 
further investigate this phenomenon, furamidine and MPP could be administered 
concomitantly to rats or isolated, perfused rat kidneys.  Studying furamidine 
basolateral transport in vivo or ex vivo may reveal information that cannot be 
seen by in vitro experiments alone.   
Possible Mechanisms of Nephrotoxicity 
There is some correlation between the location of the kidney pathology in 
pafuramidine-induced delayed nephrotoxicity patients and the location of 
furamidine accumulation.  However, while this correlation may be useful in 
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assessing potential risk of CPD-0801 nephrotoxicity (likely lower), it does not 
provide extensive information about the mechanism of toxicity.  The 
pafuramidine-induced delayed nephrotoxicity in humans was sub-clinical until 
over 40 days after the last dose.  The delayed nature of the nephrotoxicity is 
commensurate with an immune-mediated response.  In contrast to an immune 
based mechanism, the pathology reports from the two patient biopsy samples 
indicated no protein aggregations, very little if any glomerular damage, and no 
immune complexes (Olson, 2010).  Pathology alone seems to indicate that 
pafuramidine-induced nephrotoxicity is similar to other drug-induced 
nephrotoxicities that present with tubulointerstitial nephritis, nephroses and 
minimal change disease (in the case of NSAIDs) (Schrier, 2007; Greenberg, 
2009).  However, standard drug-induced nephrotoxicities are acute, occurring 
during or within days after dosing (Greenberg, 2009).  The contradiction between 
the pathology and the delayed nature of pafuramidine-induced delayed 
nephrotoxicity requires further study which may not be feasible given the lack of 
human tissue samples.   
Another possibility exists, that the toxicity seen in humans was not actually 
delayed, but was progressive.  This can occur when the mitochondria are 
damaged slowly over time until finally the cell undergoes apoptosis (Greenberg, 
2009; Quiros et al., 2010).  Kidney cells could shut down slowly, and sub-
clinically, until enough functionality was lost that the patient became 
symptomatic.  Sub-cellular co-localization studies, discussed earlier, may support 
a mitochondria-based mechanism of nephrotoxicity.  In addition, high content 
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imaging studies currently under development at The Hamner Institute may reveal 
mitochondrial deficiencies in cells treated with furamidine.  Also at The Hamner 
Institute, a rodent pafuramidine-induced nephrotoxicity model is under 
development.   
A rodent nephrotoxicity model of pafuramidine would provide a platform to 
further study the mechanism of pafuramidine-induced nephrotoxicity.  Once this 
model is developed, basolateral uptake of furamidine could be inhibited, provided 
that the uptake transporters are identified, as was done with cisplatin (Tanihara 
et al., 2009).  The lack of furamidine uptake should attenuate the nephrotoxicity, 
thus demonstrating the connection between accumulation and toxicity.  
Conversely, diamidine efflux could be inhibited through concomitant 
administration of pyrimethamine with CPD-0801 which should cause CPD-0801 
accumulation to mimic furamidine accumulation.  The subsequent nephrotoxicity 
would also demonstrate the accumulation-toxicity relationship.   
Conclusions 
In an effort to understand the mechanisms behind the observed 
differences in kidney accumulation and distribution of furamidine and CPD-0801, 
new understandings about substrate selectivity in renal proximal tubule cells 
were revealed.  CPD-0801 and furamidine differ only by the addition of two 
nitrogens.  The similarity in their structures is reflected in the apical efflux of both 
compounds, as both diamidines were MATE1 substrates.  The basolateral 
uptake of CPD-0801 and furamidine from the blood was expected to be mediated 
by OCT1 and/or OCT2 because like MATE1, OCT1/2 have broad specificity for 
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organic cations.  However, basolateral transport of both diamidines seems to be 
OCT1/2 independent.  It seems the primary reason a larger percentage of the 
dose was not eliminated renally, like so many other small organic cations, is that 
both diamidines have a very low unbound fraction in the kidney.  This work 
demonstrates that seemingly small differences in structure can have important 
physiologic implications for renal uptake, accumulation and excretion.   
In the process of investigating mechanisms for the differences in CPD-
0801 and furamidine kidney accumulation, several imaging and analytical 
techniques were used.  Development of an anti-pentamidine monoclonal 
antibody led to the novel use of inhibitory enzyme-linked immunosorbant assays 
(IELISAs) and immunostaining with a small molecule, no longer just for proteins.  
Additionally, there are several translational implications associate with this work 
that may impact the future development of CPD-0801 for treatment of Human 
African trypanosomiasis (HAT).  Based on the data presented in this work, the 
likelihood of continued CPD-0801 development for the treatment of HAT has 
been greatly increased.   
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Appendix I: 
Mab 1.85.72 Binding to Pafuramidine and Its Metabolites 
 
Chapter 2 discusses the use of an anti-pentamidine monoclonal antibody 
(Mab) for detection of CPD-0868 metabolism.  As part of that study, experiments 
were conducted to investigate whether Mab 1.85.72 (a specific anti-pentamidine 
Mab) was reactive against more recently synthesized compounds, including 
pafuramidine and its metabolites.  Results from the pafuramidine series were not 
conclusive due to several aberrations in the data, which we hypothesize may be 
due to contamination of the standards tested.  The standards were synthesized 
powder, dissolved in tissue culture grade DMSO and diluted to the appropriate 
concentrations.  Initially, it was anticipated that pafuramidine metabolism could 
also be monitored using Mab 1.85.72 in the IELISA.  However, these data show 
that contamination of the standards was too extensive for confident EC50 
calculations, a common measurement of antibody binding.   
It has been shown that pafuramidine is metabolized to furamidine through 
a series of O-demethylations and N-reductions by cytochrome P450s and b5/b5 
reductases (Figure 4) (Saulter et al., 2005; Wang et al., 2006; Wang et al., 
2007).  These metabolites are referred to as M1 (DB775), M2 (DB290), M3 
(DB810), M4 (DB835) and furamidine (DB75).  The prodrug, pafuramidine, and 
its metabolites were tested for reactivity to Mab 1.85.72.  The series was 
analyzed in quadruplicate using the IELISA developed specifically for this 
purpose (see Materials and Methods in Chapter 2).   
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The results from the CPD-0868 series discussed in Chapter 2 established 
that the amidine moiety is essential for Mab 1.85.72 binding.  Based on those 
results, it was expected that pafuramidine, M1 and M2 would not bind to the Mab 
and would have very high EC50 values, possibly exceeding the maximum 
concentrations tested.  The amidine-containing compounds, M3, M4 and 
furamidine were expected to have a high affinity for the antibody and have 
relatively lower EC50 values.   
In contrast to expectations, the non-amidine containing M1 metabolite had 
an abnormally low EC50 (Table 11), similar to what would be expected with an 
amidine containing compound.  The EC50 of pafuramidine was also lower than 
expected, but as anticipated, M2 did not attain 50% inhibition, even at the highest 
concentration.  Looking at the amidine-containing compounds, M4 was expected 
to bind with an affinity similar to M3; however, the EC50 of M4 was 10 times 
higher than M3.  Furamidine was consistent with expectations, having the lowest 
EC50 value.   
Based on the unexpected IELISA data, we hypothesized that the purity of 
the standards synthesized for the pafuramidine series was too low to obtain 
accurate EC50 values by IELISA.  The most reasonable cause for the unforeseen 
results is contamination of the presumed pure standards with other metabolites.  
Nevertheless, there are alternative explanations.  It is possible that the antibody 
recognizes an unknown epitope in non-amidine containing compounds such as 
M1.  However, the high accuracy and precision obtained with the CPD-0868 
series, and the consistent recognition of a variety of diamidine compounds 
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(Chapter 2), makes this explanation unlikely.  An error in the two methods that 
were used (IELISA and LC/MS/MS) was eliminated as an alternative hypothesis 
because both sets of data support the contamination hypothesis.  Using these 
two very different methods, we can be assured that the contamination is not an 
artifact of either assay.  Finally, the storage conditions (high grade DMSO at -
20°C) could have introduced an impurity causing the aberrant data.  Such a 
systematic impurity would likely affect all the samples, but both M2 and 
furamidine are relatively pure.    
The IELISA data suggest significant contamination of two of the non-
amidine containing compounds: pafuramidine and M1 (Figure 23 and Figure 
24); if no binding occurred, we would expect to see a horizontal line at 100%, 
instead, an “S” shaped curve was observed, indicating some Mab binding.  The 
contamination hypothesis is supported by the corresponding LC/MS/MS data, 
which indicated that pafuramidine and M1 were contaminated (2-3% and up to 
10%, respectively) with M3 and furamidine, both of which contain amidine 
moieties (Table 12).  M2 is over 98% pure, but may have a small amount of M4 
contamination, explaining the appearance, in the IELISA results, of limited 
binding at very high concentrations.  The amidine-containing compound, M4, 
cannot be quantified due the lack of a sufficiently pure standard.  As seen on the 
LC/MS/MS chromatogram, the M4 standard is mostly M2, which is not 
recognized by the antibody (Figure 27); this may explain the surprisingly low 
Mab binding affinity seen by IELISA.  M3 and furamidine, both amidine-
containing compounds, exhibited some contamination (Figure 26 and Figure 
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28).  However, the contamination was only with each other and M4, all of which 
contain an amidine group and are indistinguishable by the IELISA.  Furamidine 
seems to be one of the cleanest samples, containing no known contaminants, 
confirming that Mab 1.85.72 does bind to this diamidine sufficiently for use in 
immunostaining methods (seen in Chapter 3).   
The anomalies in the pafuramidine series can be explained by 
contamination of the standards.  Pure standards are necessary to ascertain 
whether this antibody could be used to detect pafuramidine metabolism.  Based 
on previous work, solid phase extraction (Sturk, 2005) was considered to further 
purify the samples.  Due to the extent of contamination, significantly detectable 
amounts of contaminant would likely still be present after such an extraction.  
Given the inability to obtain sufficiently pure standards, use of the IELISA with the 
pafuramidine series was abandoned.   
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Compound EC50 (nM) SEM
a of EC50 Binding? 
Pafuramidine 498 0.1 some 
M1 42.4 0.02 yes 
M2 1084 0.5 negligible 
M3 26.4 0.02 yes 
M4 256 0.03 some 
Furamidine 17.6 0.02 yes 
Table 11 EC50s of Mab 1.85.72 binding to pafuramidine and its metabolites.   
a SEM indicates the standard error of the means of eight replicates.   
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Figure 23 Pafuramidine IELISA and LC/MS/MS data.  The IELISA concentration 
curve for pafuramidine (DB289) is shown above.  The LC/MS/MS chromatogram 
(below) indicates the presence of M3 in the pafuramidine sample which may 
explain why Mab 1.85.72 seems to bind pafuramidine at high concentrations.   
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Figure 24 M1 IELISA and LC/MS/MS data.  The IELISA concentration curve for 
M1 (DB775) is shown above.  The LC/MS/MS chromatogram (below) indicates 
the presence of M3, M4 and some furamidine in the M1 sample which may 
explain why Mab 1.85.72 seems to bind M1 despite its lack of amidine.   
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Figure 25 M2 IELISA and LC/MS/MS data.  The IELISA concentration curve for 
M2 (DB290) is shown above.  The LC/MS/MS chromatogram (below) indicates 
the presence of a small amount of M4 that only slightly affects the IELISA 
binding curve.   
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Figure 26 M3 IELISA and LC/MS/MS data.  The IELISA concentration curve for 
M3 (DB810) is shown above.  The LC/MS/MS chromatogram (below) indicates 
the presence of furamidine in the M3 sample, but since the Mab binds to both M3 
and furamidine, this contamination cannot be distinguished by the IELISA.   
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Figure 27 M4 IELISA and LC/MS/MS data.  The IELISA concentration curve for 
M4 (DB835) is shown above.  The LC/MS/MS chromatogram (below) indicates 
the presence of M4, furamidine, but mostly M2.  Since M2 is the main constituent 
of the M4 sample and does not bind the Mab, the IELISA seems to indicate a 
much higher EC50 than would be expected based on the structure of M4.   
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Figure 28 Furamidine IELISA and LC/MS/MS data.  The IELISA concentration 
curve for furamidine (DB75) is shown above.  The LC/MS/MS chromatogram 
(below) indicates the presence of M4 in addition to the furamidine, but since M4 
also contains an amidine group, it is unlikely this contamination affects the 
IELISA results.   
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Standard % known compound in standard % 
contam-
ination 
% non-
amidine 
% 
amidine 
 
Pafur. M1 M2 M3 Fur. 
Pafur. 98.3 NP NP 2.4 0.2 2.6 98.3 2.6 
M1 < 0 107.0 0.2 8.0 1.7 9.9 107.2 9.7 
M2 < 0 NP 98.1 NP NP 0.0 98.1 0.0 
M3 < 0 NP NP 99.4 11.4 11.4 0.0 110.8 
Fur. < 0 NP NP NP 161.0 0.0 0.0 161.0 
Table 12 Percent of each compound in “pure” standards by LC/MS/MS.  All data 
were taken from the 1000 ng/mL samples in the calibration curves.  M4 is not 
included because no sample pure enough for quantification could be obtained.   
Pafur.: pafuramidine 
Fur.: furamidine 
Red indicates compounds which do not bind to Mab 1.85.72.   
Green indicates compounds which likely bind to Mab 1.85.72.   
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Appendix II:  
Chromatography Protocols 
 
High Performance Liquid Chromatography tandem Mass 
Spectrometry (LC/MS/MS) 
This methodology was used for analysis of kidney tissue and plasma from 
in vivo, kidney slice and binding studies discussed in Chapter 3.  Chemical 
sources are listed in the Materials and Methods section of Chapter 3.   
Sample Preparation 
This method of sample preparation was designed to minimize excessive 
sample handling by eliminating a traditionally used dry-down step which is time 
and resource consuming.  Additionally, the dry-down step may lead to 
degradation of the samples as the concentration of acid increases, and could 
perhaps lead to sample loss during resuspension.  Finally, the sample 
preparation method does not necessitate repeated pipetting of volumes less than 
25 μL to insure the highest accuracy and precision in the preparation process.   
Twenty-five microliters of plasma or kidney homogenate were added to 25 
μL DMSO, mixed and precipitated with 1:7 water:methanol containing 0.1% 
trifluoroacetic acid (TFA).  For tissue binding samples, 25 μL of tissue was mixed 
with 25 μL of fresh buffer (and vice versa) before an additional 25 μL of DMSO 
was added to compensate for any matrix effects caused by small molecules that 
may have crossed the dialysis membrane.  Calibration standards (2.5 ng/mL to 
10,000 ng/mL) were prepared in DMSO and added 1:1 to matrix (kidney 
homogenate, plasma or a 1:1 mixture of tissue and buffer) then precipitated.  The 
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appropriate internal standard was added to the precipitation solution for a final 
concentration of approximately 100 ng/mL in each sample.  Prodrug, M1, M2, M3 
and active diamidine for both the pafuramidine and CPD-0868 series (Figure 4) 
were quantified using d6-pafuramidine (prodrug, M1, M2) or d6-furamidine (M3, 
diamidine) as the internal standard.  The lower limit of quantification was 2.5 
ng/mL.  There are no quantification standards for M4 or glucuronidated 
metabolites for either series, but they were monitored using estimated transitions.   
Chromatography 
A Shimadzu solvent delivery system (Columbia, MD, USA) and a Leap 
HTC Pal thermostated autosampler (Carrboro, NC, USA) connected to an 
Applied Biosystems API 4000 triple quadruple mass spectrometer with a 
TurboSpray® ion source (Applied Biosystems, Foster City, CA, USA) were used 
for this analytical study. Tuning, operation, integration and data analysis were 
performed in positive mode using multiple reaction monitoring (Analyst® software 
v.1.4.1, Applied Biosystems, Foster City, CA, USA).  Separation was 
accomplished using an Aquasil® C18, 50x2.1 mm column, with a 5 µm particle 
size (ThermoElectron, San Jose, CA, USA).  Analysis required 4 µL of sample 
and a solvent flow of 0.35 mL/min.  The two mobile phases were: mobile phase A 
(100% water containing 35mM formic acid with 15 mM ammonium formate) and 
mobile phase B (20% water and 80% acetonitrile, containing 35mM formic acid 
with 15 mM ammonium formate).  Initial gradient conditions were 10% mobile 
phase B.  This was held for 0.8 min while the eluent was directed to waste.  From 
0.8 min to 7.0 min, the mobile phase composition increased linearly to 80% 
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mobile phase B and the eluent was directed to the mass spectrometer.  From 7.0 
min to 7.6 min, the mobile phase composition increased linearly to 100% mobile 
phase B and held at 100% mobile phase B until 8 min.  At 9 min, the eluent was 
again directed to waste and the column was equilibrated with 10% mobile phase 
B.  Total runtime, including equilibration, was 10 minutes per injection.  
Calibration standards were injected in duplicate and calibration curves were 
constructed using peak area ratios of analyte and internal standard using 1/x2 
(linear) or 1/x (quadratic) weighting scheme.   
Mass Spectrometry 
Transitions used were as follows:   
 pafuramidine (365.1334.1) 
 M1 [pafuramidine] (351.1320.1) 
 M2 [pafuramidine] (337.3320.0) 
 M3 [pafuramidine] (335.5288.0) 
 M4 [pafuramidine] (monitoring only, 321.4304.1) 
 furamidine (305.3288.1) 
 CPD-0868 (367.1336.1) 
 M1 [CPD-0868] (353.1322.1) 
 M2 [CPD-0868] (339.3322.0) 
 M3 [CPD-0868] (337.5290.0) 
 M4 [CPD-0868] (monitoring only, 323.4306.1) 
 CPD-0801 (307.3290.2) 
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 d6-furamidine (internal standard for amidines, 313.3296.1) 
 d6-pafuramidine (internal standard for non-amidino compounds, 
373.1342.0) 
To eliminate instrument error due to in source fragmentation of adducts, care 
was taken to ensure analytical separation between prodrug and the various 
metabolites, including the diamidines.  All points on the curve back-calculated to 
within 15% of the nominal value. 
Validation 
The LC/MS/MS method used in this work is not currently validated for 
experiments outside the realm of research.  However, the tools are available to 
do so if detailed sensitivity, specificity, accuracy and precision were needed.   
To validate this method, all standard curves must be prepared in duplicate 
(meaning separate precipitations) in the appropriate matrix.  Validation must be 
done for each matrix and each compound separately.  In addition to the standard 
curves, quality control samples (QCs) would be needed at: the lower limit of 
quantification (LLoQ, the lowest standard in the curve), low QC (three times the 
lowest standard), medium QC (middle concentration that is not a standard), and 
high QC (80% of the highest standard, again not at a level that is a standard).  
Each QC must be done in six replicates, each a separate precipitation, preferably 
also weighing to compound powder separately to create stock solutions 
separately from those used for the standard curves.   
For the LC/MS/MS method to be considered validated for a given 
compound in a given matrix, both standard curves must be consistent.  
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Additionally, the LLoQ must be on average within 20% of the nominal value, and 
more than three times baseline.  All other QCs (low, medium and high) on 
average must be with 15% of the nominal value.  This controls for each aspect of 
the method (accuracy) and provides intra-day variability (precision).  The 
validation process as described here must be repeated, in its entirety, on three 
separate days.  Average accuracies must be 20% and 15% for LLoQ samples 
and QCs, respectively, on each day.  Using this data, inter-day variability could 
be assessed by ANOVA.   
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Sample Chromatograms 
 
  
Figure 29 Untreated rat plasma analyzed by LC/MS/MS.   
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Figure 30 Lower limit of quantification standard (2.5 ng/mL) for CPD-0801 in rat 
plasma analyzed by LC/MS/MS.   
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Figure 31 Lower limit of quantification standard (2.5 ng/mL) for furamidine in rat 
plasma analyzed by LC/MS/MS.   
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Figure 32 Untreated rat kidney analyzed by LC/MS/MS.   
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Figure 33 Lower limit of quantification standard (2.5 ng/mL) for CPD-0801 in rat 
kidney analyzed by LC/MS/MS.   
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Figure 34 Lower limit of quantification standard (2.5 ng/mL) for furamidine in rat 
kidney analyzed by LC/MS/MS.   
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High Performance Liquid Chromatography with Fluorescence 
Detection (HPLC-FLD) 
This methodology was used to detect diamidines (furamidine and CPD-
0801) in rat urine and cell lysates as described in Chapter 3.  Chemical sources 
are listed in the Materials and Methods section of Chapter 3.   
Sample Preparation 
Samples were prepared as described for LC/MS/MS with few alterations.  
The standard curves for cell lysate samples were mixed 1:1 with precipitation 
solution.  Lysate solution was 15% methanol in water with 0.1% trifluoroacetic 
acid (TFA).  Precipitation solution was 1:7 water:methanol containing 0.1% TFA.  
All samples and calibration standards with cell lysate had 25 μL of water added 
to dilute the solvent.  Urine samples were prepared as described for LC/MS/MS, 
but without the addition of an internal standard.  All internal standards tested 
coeluted with furamidine or CPD-0801 peaks rendering them ineffective.  
Compounds tested for use as internal standards include: furamidine (for CPD-
0801), CPD-0801 (for furamidine), 5-amidino-2-(4-amidinophenyl)benzofuran 
(150/49 by Otto Dann), and M3 for both pafuramidine and CPD-0868.   
Chromatography 
An Agilent solvent delivery system (Santa Clara, CA, USA) and a Leap 
HTC Pal thermostated autosampler (Carrboro, NC USA) were used for this 
analytical study.  Fluorescence detection (Agilent, Santa Clara, CA, USA) was 
done at an excitation wavelength of 359 nm and an emission of 462 nm.  
Separation was accomplished using a Zorbax Bonus-RP, 150x2.1 mm column, 
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with a 3.5 µm particle size at 40°C (column and column heater: Agilent, Santa 
Clara, CA, USA).  Analysis required 5 µL of sample and a solvent flow of 0.35 
mL/min.  The two mobile phases were: mobile phase A (100% water containing 
35mM formic acid with 15 mM ammonium formate) and mobile phase B (20% 
water and 80% acetonitrile, containing 35mM formic acid with 15 mM ammonium 
formate).  Initial gradient conditions were 0% mobile phase B.  This was held for 
1 min.  From 1 min to 10 min, the mobile phase composition increased linearly to 
100% mobile phase B.  From 10 min to 12 min, 100% mobile phase B was held 
to wash out the column.  From 12 to 12.5 min, the mobile phase composition 
decreased linearly to 0% mobile phase B.  At 12.5 min, the column was 
equilibrated with 0% mobile phase B.  Total runtime, including equilibration, was 
18 minutes per injection.  Calibration standards were injected in duplicate and 
calibration curves were constructed using peak area analyte.   
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Sample Chromatograms 
  
   
Figure 35 Calibration curves (1000 ng/mL) in rat urine by HPLC-FLD.  Curves 
indicate CPD-0801 (red), furamidine (blue) and a blank (green). 
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Figure 36 hMATE1 transfected CHO cells analyzed by HPLC-FLD.  CHO-
hMATE1 cells were treated with MPP, and CPD-0801 (red) or furamidine (blue).  
Blank is shown in green.   
